deelee的个人主页 - 老虎社区

deelee

deelee

Deelee

IP属地：未知

397关注

9粉丝

1主题

0勋章

2021-07-14

唱歌不会啦，跳舞可能！

Why the CDC and FDA Just Slapped Down Pfizer and Moderna

2021-07-12

打，第三针，一定要。

抱歉，原内容已删除

2021-07-09

又来，为什么PFE股票涨这么慢！

辉瑞(PFE.US)和BioNTech(BNTX.US)计划在8月份试验针对Delta异株疫苗

2021-07-02

敢敢加仓

抱歉，原内容已删除

2021-06-30

为什么辉瑞股票最近不能涨！

抱歉，原内容已删除

2021-06-29

加仓

抱歉，原内容已删除

2021-06-23

加仓，辉瑞。

抱歉，原内容已删除

2021-06-22

加仓

美联储政策转向在即，这是五种应对方式

2021-06-21

PFE 加仓

5 Stocks To Watch For June 21, 2021

2021-06-21

加仓

格力超级员工持股计划来了！员工可五折"买股票"

2021-06-21

加仓

抱歉，原内容已删除

2021-06-19

完了完了

抱歉，原内容已删除

2021-06-18

美联储慌？你慌它都还没慌啦！

抱歉，原内容已删除

2021-06-18

加仓

加拿大皇家银行：将辉瑞(PFE.N)目标价从43美元升至44美元。

2021-06-17

赞，加仓

Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts

2021-06-16

哈哈，捐到拍。

抱歉，原内容已删除

2021-06-13

加仓，机会来了。

Science Sides with Pfizer, Despite Vaccine Fears

2021-06-13

加仓

Vietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use

2021-06-13

又休息

提醒：端午休市安排来了！港股6月14日休市一天

2021-06-12

怎么可能，加仓

COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3567856328974744","uuid":"3567856328974744","gmtCreate":1604843559678,"gmtModify":1617280994652,"name":"deelee","pinyin":"deelee","introduction":"","introductionEn":"","signature":"Deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":397,"tweetSize":113,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-3","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识航海家","description":"观看学堂课程满50节","bigImgUrl":"https://static.tigerbbs.com/21acbb5884e07b96522d8d84c4b7acea","smallImgUrl":"https://static.tigerbbs.com/e4e8dc2edfbfee912f4e68fe6c23b3f0","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":145465294,"gmtCreate":1626238674318,"gmtModify":1633928717796,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"唱歌不会啦，跳舞可能！","listText":"唱歌不会啦，跳舞可能！","text":"唱歌不会啦，跳舞可能！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145465294","repostId":"2151550481","repostType":2,"repost":{"id":"2151550481","kind":"highlight","pubTimestamp":1626231600,"share":"https://www.laohu8.com/m/news/2151550481?lang=&edition=full","pubTime":"2021-07-14 11:00","market":"us","language":"en","title":"Why the CDC and FDA Just Slapped Down Pfizer and Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2151550481","media":"Motley Fool","summary":"There's a bit of a brouhaha over booster doses.","content":"<p><b>Pfizer</b> (NYSE:PFE)&nbsp;and&nbsp;<b>Moderna</b> (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control &amp; Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The FDA granted quick approvals to both drugmakers' COVID-19 vaccines last December. The CDC has encouraged Americans to receive both vaccines.</p>\n<p>However, some might now think that the honeymoon is over. Pfizer and Moderna have recently expressed support for booster doses. The CDC and FDA issued a joint public statement last week that appeared to contradict this view. Here's why the two federal agencies just slapped down Pfizer and Moderna.</p>\n<p><img src=\"https://static.tigerbbs.com/9282ceea65d6d87d5e9d88017233aa2a\" tg-width=\"700\" tg-height=\"408\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>A quick and forceful response</h3>\n<p>On July 8, Pfizer chief scientific officer Mikael Dolsten told Reuters in an interview that his company and its partner, <b>BioNTech</b> (NASDAQ:BNTX), plan to soon file for U.S. and European emergency use authorizations (EUA) for a third booster dose. In a separate interview on the same day with CTV News Channel, Moderna co-founder Derrick Rossi said that \"a booster is almost certainly the way.\"</p>\n<p>Rossi doesn't serve on Moderna's management team or board of directors,&nbsp;so his comments didn't represent the biotech's official stance. However, Moderna CEO Stephane Bancel stated in the company's first-quarter conference call: \"We have said for right now that we believe booster shots will be needed as we believe that the virus is not going away.\"</p>\n<p>Later in the day on July 8, the CDC and FDA issued a joint statement on vaccine boosters. The agencies stated:</p>\n<blockquote>\n Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively. We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed.\n</blockquote>\n<p>The CDC-FDA statement appeared to be a direct slap-down -- especially to Pfizer. But why would the agencies respond so quickly and forcefully? The main reason is probably that they don't want to worry Americans who have already been vaccinated, nor give any reason for unvaccinated individuals to delay receiving a vaccine.</p>\n<p>However, I suspect that the FDA, in particular, also had another motivation. The agency doesn't want to be viewed as having too cozy of a relationship with any drugmaker. It has been heavily criticized for the process followed in approving <b>Biogen</b>'s Alzheimer's disease drug Aduhelm. FDA Commissioner Dr. Janet Woodcock even requested an independent investigation into interactions between the agency's staff and Biogen during the review process for the drug.</p>\n<h3>Reconciliable differences</h3>\n<p>Despite the seeming squabble, I don't think that the CDC and the FDA are really in direct opposition to what Pfizer and Moderna have said. There are several similarities between their public statements.</p>\n<p>Both sides agree that the currently available messenger RNA (mRNA) vaccines remain effective at preventing COVID-19. Both also look to data to form their views.</p>\n<p>Pfizer and BioNTech stated last week that their initial data indicates that a third booster dose generates significantly higher antibody levels than only two doses -- five to 10 times more. The CDC and FDA haven't seen this data yet, though. Pfizer and BioNTech expect to submit the data to the FDA as well as to the European Medicines Agency and other regulatory authorities within the next few weeks.</p>\n<p>The differences between the CDC-FDA view and Pfizer-BioNTech-Moderna perspective appear to be mainly related to timing. The drugmakers believe they've seen enough data to know now that booster doses will be needed, while the federal agencies think they need to see more data but aren't ruling out the potential need for booster doses.</p>\n<h3>Why all of this matters</h3>\n<p>Clearly, Pfizer, BioNTech, and Moderna benefit financially if booster doses are needed. The more COVID-19 vaccine doses are required, the higher the companies' sales will be and the better the vaccine stocks will likely perform.</p>\n<p>Government agencies aren't (or at least shouldn't be) concerned with how much money any of these companies make. However, they are responsible for promoting public health. If booster doses are what it takes to effectively fight the spread of COVID-19, they'll be authorized.</p>\n<p>My hunch is that the recent real-world data from Israel gives a good clue as to what will happen going forward. That data found only 64% efficacy of the Pfizer-BioNTech vaccine against COVID-19 overall, down from 94% a month earlier, primarily because of the spread of the delta variant. If a third booster dose can get efficacy closer to the initial level, it would be shocking if authorizations aren't granted.</p>\n<p>Pfizer, Moderna, the CDC, and the FDA might not always be in harmony. However, I predict they'll soon be singing from the same page when it comes to the need for booster doses.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why the CDC and FDA Just Slapped Down Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy the CDC and FDA Just Slapped Down Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151550481","content_text":"Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The FDA granted quick approvals to both drugmakers' COVID-19 vaccines last December. The CDC has encouraged Americans to receive both vaccines.\nHowever, some might now think that the honeymoon is over. Pfizer and Moderna have recently expressed support for booster doses. The CDC and FDA issued a joint public statement last week that appeared to contradict this view. Here's why the two federal agencies just slapped down Pfizer and Moderna.\n\nImage source: Getty Images.\nA quick and forceful response\nOn July 8, Pfizer chief scientific officer Mikael Dolsten told Reuters in an interview that his company and its partner, BioNTech (NASDAQ:BNTX), plan to soon file for U.S. and European emergency use authorizations (EUA) for a third booster dose. In a separate interview on the same day with CTV News Channel, Moderna co-founder Derrick Rossi said that \"a booster is almost certainly the way.\"\nRossi doesn't serve on Moderna's management team or board of directors, so his comments didn't represent the biotech's official stance. However, Moderna CEO Stephane Bancel stated in the company's first-quarter conference call: \"We have said for right now that we believe booster shots will be needed as we believe that the virus is not going away.\"\nLater in the day on July 8, the CDC and FDA issued a joint statement on vaccine boosters. The agencies stated:\n\n Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively. We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed.\n\nThe CDC-FDA statement appeared to be a direct slap-down -- especially to Pfizer. But why would the agencies respond so quickly and forcefully? The main reason is probably that they don't want to worry Americans who have already been vaccinated, nor give any reason for unvaccinated individuals to delay receiving a vaccine.\nHowever, I suspect that the FDA, in particular, also had another motivation. The agency doesn't want to be viewed as having too cozy of a relationship with any drugmaker. It has been heavily criticized for the process followed in approving Biogen's Alzheimer's disease drug Aduhelm. FDA Commissioner Dr. Janet Woodcock even requested an independent investigation into interactions between the agency's staff and Biogen during the review process for the drug.\nReconciliable differences\nDespite the seeming squabble, I don't think that the CDC and the FDA are really in direct opposition to what Pfizer and Moderna have said. There are several similarities between their public statements.\nBoth sides agree that the currently available messenger RNA (mRNA) vaccines remain effective at preventing COVID-19. Both also look to data to form their views.\nPfizer and BioNTech stated last week that their initial data indicates that a third booster dose generates significantly higher antibody levels than only two doses -- five to 10 times more. The CDC and FDA haven't seen this data yet, though. Pfizer and BioNTech expect to submit the data to the FDA as well as to the European Medicines Agency and other regulatory authorities within the next few weeks.\nThe differences between the CDC-FDA view and Pfizer-BioNTech-Moderna perspective appear to be mainly related to timing. The drugmakers believe they've seen enough data to know now that booster doses will be needed, while the federal agencies think they need to see more data but aren't ruling out the potential need for booster doses.\nWhy all of this matters\nClearly, Pfizer, BioNTech, and Moderna benefit financially if booster doses are needed. The more COVID-19 vaccine doses are required, the higher the companies' sales will be and the better the vaccine stocks will likely perform.\nGovernment agencies aren't (or at least shouldn't be) concerned with how much money any of these companies make. However, they are responsible for promoting public health. If booster doses are what it takes to effectively fight the spread of COVID-19, they'll be authorized.\nMy hunch is that the recent real-world data from Israel gives a good clue as to what will happen going forward. That data found only 64% efficacy of the Pfizer-BioNTech vaccine against COVID-19 overall, down from 94% a month earlier, primarily because of the spread of the delta variant. If a third booster dose can get efficacy closer to the initial level, it would be shocking if authorizations aren't granted.\nPfizer, Moderna, the CDC, and the FDA might not always be in harmony. However, I predict they'll soon be singing from the same page when it comes to the need for booster doses.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":146181081,"gmtCreate":1626058958443,"gmtModify":1633930539458,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"打，第三针，一定要。","listText":"打，第三针，一定要。","text":"打，第三针，一定要。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/146181081","repostId":"2150851335","repostType":2,"isVote":1,"tweetType":1,"viewCount":1177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":141380571,"gmtCreate":1625838776393,"gmtModify":1633936833196,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"又来，为什么PFE股票涨这么慢！","listText":"又来，为什么PFE股票涨这么慢！","text":"又来，为什么PFE股票涨这么慢！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141380571","repostId":"2150377552","repostType":2,"repost":{"id":"2150377552","kind":"news","pubTimestamp":1625837588,"share":"https://www.laohu8.com/m/news/2150377552?lang=&edition=full","pubTime":"2021-07-09 21:33","market":"hk","language":"zh","title":"辉瑞(PFE.US)和BioNTech(BNTX.US)计划在8月份试验针对Delta异株疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2150377552","media":"智通财经","summary":"智通财经APP获悉，辉瑞和BioNTech正准备下个月开始针对Delta异株的Covid-19疫苗的临床试验，因为人们担心现有的疫苗对这种在全球大部分地区传播的毒株提供的保护不足。辉瑞和BioNTech正与美国药品监管机构进行讨论，以敲定它们的临床试验计划，预计将在8月开始研究。以色列卫生部本周的一项研究表明，BioNTech/辉瑞疫苗在预防Delta病毒引起的严重疾病和住院治疗方面的有效性为93%，但在防止感染该病毒变体方面的有效性仅为64%。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE.US)和BioNTech(BNTX.US)正准备下个月开始针对Delta异株的Covid-19疫苗的临床试验，因为人们担心现有的疫苗对这种在全球大部分地区传播的毒株提供的保护不足。</p><p>辉瑞周四表示，制药商正在开发现有疫苗的更新版本，将使用Delta异株的序列来生产。辉瑞和BioNTech正与美国药品监管机构进行讨论，以敲定它们的临床试验计划，预计将在8月开始研究。</p><p>这两家公司将率先研发针对Delta异株的疫苗，这表明这种高度传染性的毒株可能能够逃避现有的疫苗，需要采取新的措施来应对它。</p><p>美国疾病控制与预防中心数据显示，Delta异株目前是美国的主要毒株，同时占英国新冠病毒病例的90%以上。</p><p>辉瑞重申，在两针疫苗的第二针之后的6至12个月，需要第三针疫苗，以增强对新变种的免疫力。该公司表示，它将公布关于第三次注射效果的更明确数据，并计划在8月份向美国食品和药物管理局申请加强注射的紧急使用授权。</p><p>辉瑞指出，上个月公布的初步数据显示，两剂疫苗产生了针对Delta变体的抗体滴度，但该公司表示，疫苗效力在接种6个月后出现下降。</p><p>以色列卫生部本周的一项研究表明，BioNTech/辉瑞疫苗在预防Delta病毒引起的严重疾病和住院治疗方面的有效性为93%，但在防止感染该病毒变体方面的有效性仅为64%。</p><p>而Moderna(MRNA.US)和<a href=\"https://laohu8.com/S/JNJ\">强生</a>(JNJ.US)均表示，早期数据显示，他们的疫苗产生了针对Delta的抗体。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞(PFE.US)和BioNTech(BNTX.US)计划在8月份试验针对Delta异株疫苗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞(PFE.US)和BioNTech(BNTX.US)计划在8月份试验针对Delta异株疫苗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 21:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/511262.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，辉瑞(PFE.US)和BioNTech(BNTX.US)正准备下个月开始针对Delta异株的Covid-19疫苗的临床试验，因为人们担心现有的疫苗对这种在全球大部分地区传播的毒株提供的保护不足。辉瑞周四表示，制药商正在开发现有疫苗的更新版本，将使用Delta异株的序列来生产。辉瑞和BioNTech正与美国药品监管机构进行讨论，以敲定它们的临床试验计划，预计将在8月开始研究。这...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/511262.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e559c5a8390713a5a8d4b07a2667368d","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://www.zhitongcaijing.com/content/detail/511262.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2150377552","content_text":"智通财经APP获悉，辉瑞(PFE.US)和BioNTech(BNTX.US)正准备下个月开始针对Delta异株的Covid-19疫苗的临床试验，因为人们担心现有的疫苗对这种在全球大部分地区传播的毒株提供的保护不足。辉瑞周四表示，制药商正在开发现有疫苗的更新版本，将使用Delta异株的序列来生产。辉瑞和BioNTech正与美国药品监管机构进行讨论，以敲定它们的临床试验计划，预计将在8月开始研究。这两家公司将率先研发针对Delta异株的疫苗，这表明这种高度传染性的毒株可能能够逃避现有的疫苗，需要采取新的措施来应对它。美国疾病控制与预防中心数据显示，Delta异株目前是美国的主要毒株，同时占英国新冠病毒病例的90%以上。辉瑞重申，在两针疫苗的第二针之后的6至12个月，需要第三针疫苗，以增强对新变种的免疫力。该公司表示，它将公布关于第三次注射效果的更明确数据，并计划在8月份向美国食品和药物管理局申请加强注射的紧急使用授权。辉瑞指出，上个月公布的初步数据显示，两剂疫苗产生了针对Delta变体的抗体滴度，但该公司表示，疫苗效力在接种6个月后出现下降。以色列卫生部本周的一项研究表明，BioNTech/辉瑞疫苗在预防Delta病毒引起的严重疾病和住院治疗方面的有效性为93%，但在防止感染该病毒变体方面的有效性仅为64%。而Moderna(MRNA.US)和强生(JNJ.US)均表示，早期数据显示，他们的疫苗产生了针对Delta的抗体。","news_type":1},"isVote":1,"tweetType":1,"viewCount":912,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":156806491,"gmtCreate":1625207386913,"gmtModify":1633942530457,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"敢敢加仓","listText":"敢敢加仓","text":"敢敢加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/156806491","repostId":"1190839016","repostType":4,"isVote":1,"tweetType":1,"viewCount":2194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":153576645,"gmtCreate":1625039703287,"gmtModify":1633945558096,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"为什么辉瑞股票最近不能涨！","listText":"为什么辉瑞股票最近不能涨！","text":"为什么辉瑞股票最近不能涨！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153576645","repostId":"2147894605","repostType":2,"isVote":1,"tweetType":1,"viewCount":1840,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":159987550,"gmtCreate":1624936296970,"gmtModify":1633946764588,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159987550","repostId":"2147855283","repostType":4,"isVote":1,"tweetType":1,"viewCount":1881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":123507614,"gmtCreate":1624427907138,"gmtModify":1634006244546,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"加仓，辉瑞。","listText":"加仓，辉瑞。","text":"加仓，辉瑞。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/123507614","repostId":"2145062155","repostType":2,"isVote":1,"tweetType":1,"viewCount":1584,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":120360036,"gmtCreate":1624300441625,"gmtModify":1634008162162,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/120360036","repostId":"2145170778","repostType":4,"repost":{"id":"2145170778","kind":"highlight","weMediaInfo":{"introduction":"中国大陆领先的金融数据、信息和软件服务企业，总部位于上海陆家嘴金融中心。","home_visible":1,"media_name":"Wind万得","id":"99","head_image":"https://static.tigerbbs.com/c71e30d1317b4a5cb20a41998e10ac68"},"pubTimestamp":1624243561,"share":"https://www.laohu8.com/m/news/2145170778?lang=&edition=full","pubTime":"2021-06-21 10:46","market":"hk","language":"zh","title":"美联储政策转向在即，这是五种应对方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2145170778","media":"Wind万得","summary":"美联储政策制定者上周暗示，加息或比预期更快到来，这让很多投资者感到意外。投资者担心，美联储的政策转向将打击脆弱的经济复苏，并对风险资产价格造成伤害。分析师建议，尽管美联储的政策“掉头”不会突然出现，但投资者仍需将五个应对方式牢记于心。美联储的政策转变证实，经济正从周期的早期阶段走向中期。","content":"<p>美联储政策制定者上周暗示，加息或比预期更快到来，这让很多投资者感到意外。</p>\n<p>广告美股市场闻讯下跌：标普500指数过去一周下跌1.9%，至4166.45点，创下2月份以来的最大跌幅;道琼斯工业股票平均价格指数下跌1189.52点，跌幅3.4%，至33290.08点，创下2020年10月以来的最大单周跌幅。</p>\n<p>投资者担心，美联储的政策转向将打击脆弱的经济复苏，并对风险资产价格造成伤害。分析师建议，尽管美联储的政策“掉头”不会突然出现，但投资者仍需将五个应对方式牢记于心。</p>\n<p><b>1、注重上市公司质量</b></p>\n<p>美联储的政策转变证实，经济正从周期的早期阶段走向中期。在早期阶段，迅猛增长是常态，而这有利于更多的投机性股票。约翰汉考克投资管理公司(John Hancock investment Management)的联席首席投资策略师艾米丽•罗兰(Emily Roland)表示，而当前的周期转变意味着，现在是时候看好股市的优质股了。</p>\n<p>具体来看，罗兰指出，投资者更应关注那些具有利润率更高、资产负债表强劲、自由现金流良好和股本回报率更高等特点的公司。而其中，优质股与技术板块的叠加领域尤其受分析师青睐，罗兰指出：“技术是与优质股重叠最多的领域，能够经受住更温和的增长环境。”</p>\n<p><b>2、重新开放</b></p>\n<p>在Cambiar Investors投资组合经理布莱恩•巴里斯(Brian Barish)看来，美联储上周最大的收获是承认，极端的宽松货币政策需要相对较快地结束，这是个好消息。</p>\n<p>巴里斯说：“很多人都认为美联储采取了某种鲁莽的姿态。”“它的政策与另一场金融危机式的衰退相一致。出乎意料的是，事实并非如此。”</p>\n<p>不过，尽管现在是缩减刺激措施的时候了，但更激进的美联储也让投资者感到紧张，因为有可能出现导致下一次衰退的政策错误。</p>\n<p>在这一背景下，巴里斯认为重新开放相关的领域将继续具备优势。具体来看，巴里斯看好Uber等打车软件，以及餐饮及零售连锁店。</p>\n<p>新奥尔良Villere &amp; Co.投资组合经理桑迪•维莱尔(Sandy Villere)也认为，保持重新开放的头寸是有意义的，因为美联储加息的预期仍是在遥远的将来。“如果利率在2023年底之前都保持在低水平，那么低利率仍然需要很长一段时间，我短期内不会兑现。”</p>\n<p><b>3、小心高泡沫领域</b></p>\n<p>约翰汉考克投资管理公司策略师罗兰指出，美联储周三发出了令人困惑的复杂信号。一方面，它明确表示，最近的通胀飙升是暂时的。这是有道理的，因为通胀飙升很大程度上与供应链短缺有关。最近通货膨胀率的急剧上升也有点像海市蜃楼，因为这种比较是基于一年前疫情最严重时期暂时抑制价格。</p>\n<p>但另一方面，美联储提前了加息的时间表。罗兰指出“如果他们相信通胀是暂时的，为什么他们要提高加息预期?一种理论是，美联储担心市场投机过度。”</p>\n<p>美联储创造的过剩流动性和美国政府的财政支出，显然助长了投机领域。因此，美联储可能会对抑制导致比特币，以及GameStop和AMC等散户热门股大涨的投机行为感兴趣。</p>\n<p><b>4、削减房地产、能源和材料类股</b></p>\n<p>对普信集团(T. Rowe Price)多资产部门的资本市场策略师蒂姆•默里(Tim Murray)来说，上周美联储得到的最大启示是，它对通胀越来越警惕。他表示：“美联储不再处于自动驾驶模式。”</p>\n<p>这对那些从通胀中受益最大的市场领域来说是个坏消息。这意味着那些拥有随着通货膨胀而升值的房地产、能源和材料等实物资产的公司将受到打击。但默里认为，美联储不会为了应对通胀而扼杀经济增长。因此，工业类等其他周期性股票还有生命力。</p>\n<p><b>5、无需担心缩减恐慌</b></p>\n<p>紧缩计划已经提上日程，很可能在今年年底开始实施。在过去，这导致了标普500指数、纳斯达克综合指数和道琼斯工业平均指数的大规模抛售，即所谓的缩减恐慌(taper tantrums)。</p>\n<p>“缩减恐慌可能不会发生，”默里说。“2013年，投资者没有预料到会发生这种情况，而这一次，美联储一直在让所有人做好准备。”</p>\n<p>但同时，分析师也提示投资者不要回到成长股领域。纳斯达克综合指数下跌0.3%，至14030.38点，是上周唯一相对未受影响的主要股指。10年期美债收益率较低，在短期内对成长股有利，但美联储最终将开始加息，可能会对该领域估值造成打击。MKM Partners首席经济学家迈克尔•达尔达(Michael Darda)表示：“成长型股票仍需要一切正常，才能维持目前的估值水平。”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美联储政策转向在即，这是五种应对方式</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美联储政策转向在即，这是五种应对方式\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/99\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/c71e30d1317b4a5cb20a41998e10ac68);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Wind万得 </p>\n<p class=\"h-time\">2021-06-21 10:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>美联储政策制定者上周暗示，加息或比预期更快到来，这让很多投资者感到意外。</p>\n<p>广告美股市场闻讯下跌：标普500指数过去一周下跌1.9%，至4166.45点，创下2月份以来的最大跌幅;道琼斯工业股票平均价格指数下跌1189.52点，跌幅3.4%，至33290.08点，创下2020年10月以来的最大单周跌幅。</p>\n<p>投资者担心，美联储的政策转向将打击脆弱的经济复苏，并对风险资产价格造成伤害。分析师建议，尽管美联储的政策“掉头”不会突然出现，但投资者仍需将五个应对方式牢记于心。</p>\n<p><b>1、注重上市公司质量</b></p>\n<p>美联储的政策转变证实，经济正从周期的早期阶段走向中期。在早期阶段，迅猛增长是常态，而这有利于更多的投机性股票。约翰汉考克投资管理公司(John Hancock investment Management)的联席首席投资策略师艾米丽•罗兰(Emily Roland)表示，而当前的周期转变意味着，现在是时候看好股市的优质股了。</p>\n<p>具体来看，罗兰指出，投资者更应关注那些具有利润率更高、资产负债表强劲、自由现金流良好和股本回报率更高等特点的公司。而其中，优质股与技术板块的叠加领域尤其受分析师青睐，罗兰指出：“技术是与优质股重叠最多的领域，能够经受住更温和的增长环境。”</p>\n<p><b>2、重新开放</b></p>\n<p>在Cambiar Investors投资组合经理布莱恩•巴里斯(Brian Barish)看来，美联储上周最大的收获是承认，极端的宽松货币政策需要相对较快地结束，这是个好消息。</p>\n<p>巴里斯说：“很多人都认为美联储采取了某种鲁莽的姿态。”“它的政策与另一场金融危机式的衰退相一致。出乎意料的是，事实并非如此。”</p>\n<p>不过，尽管现在是缩减刺激措施的时候了，但更激进的美联储也让投资者感到紧张，因为有可能出现导致下一次衰退的政策错误。</p>\n<p>在这一背景下，巴里斯认为重新开放相关的领域将继续具备优势。具体来看，巴里斯看好Uber等打车软件，以及餐饮及零售连锁店。</p>\n<p>新奥尔良Villere &amp; Co.投资组合经理桑迪•维莱尔(Sandy Villere)也认为，保持重新开放的头寸是有意义的，因为美联储加息的预期仍是在遥远的将来。“如果利率在2023年底之前都保持在低水平，那么低利率仍然需要很长一段时间，我短期内不会兑现。”</p>\n<p><b>3、小心高泡沫领域</b></p>\n<p>约翰汉考克投资管理公司策略师罗兰指出，美联储周三发出了令人困惑的复杂信号。一方面，它明确表示，最近的通胀飙升是暂时的。这是有道理的，因为通胀飙升很大程度上与供应链短缺有关。最近通货膨胀率的急剧上升也有点像海市蜃楼，因为这种比较是基于一年前疫情最严重时期暂时抑制价格。</p>\n<p>但另一方面，美联储提前了加息的时间表。罗兰指出“如果他们相信通胀是暂时的，为什么他们要提高加息预期?一种理论是，美联储担心市场投机过度。”</p>\n<p>美联储创造的过剩流动性和美国政府的财政支出，显然助长了投机领域。因此，美联储可能会对抑制导致比特币，以及GameStop和AMC等散户热门股大涨的投机行为感兴趣。</p>\n<p><b>4、削减房地产、能源和材料类股</b></p>\n<p>对普信集团(T. Rowe Price)多资产部门的资本市场策略师蒂姆•默里(Tim Murray)来说，上周美联储得到的最大启示是，它对通胀越来越警惕。他表示：“美联储不再处于自动驾驶模式。”</p>\n<p>这对那些从通胀中受益最大的市场领域来说是个坏消息。这意味着那些拥有随着通货膨胀而升值的房地产、能源和材料等实物资产的公司将受到打击。但默里认为，美联储不会为了应对通胀而扼杀经济增长。因此，工业类等其他周期性股票还有生命力。</p>\n<p><b>5、无需担心缩减恐慌</b></p>\n<p>紧缩计划已经提上日程，很可能在今年年底开始实施。在过去，这导致了标普500指数、纳斯达克综合指数和道琼斯工业平均指数的大规模抛售，即所谓的缩减恐慌(taper tantrums)。</p>\n<p>“缩减恐慌可能不会发生，”默里说。“2013年，投资者没有预料到会发生这种情况，而这一次，美联储一直在让所有人做好准备。”</p>\n<p>但同时，分析师也提示投资者不要回到成长股领域。纳斯达克综合指数下跌0.3%，至14030.38点，是上周唯一相对未受影响的主要股指。10年期美债收益率较低，在短期内对成长股有利，但美联储最终将开始加息，可能会对该领域估值造成打击。MKM Partners首席经济学家迈克尔•达尔达(Michael Darda)表示：“成长型股票仍需要一切正常，才能维持目前的估值水平。”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/211b73624a3397dc62c448ac2ccbb4c7","relate_stocks":{"161125":"标普500","513500":"标普500ETF","TQQQ":"纳指三倍做多ETF","SH":"标普500反向ETF","IVV":"标普500指数ETF","QLD":"纳指两倍做多ETF","UDOW":"道指三倍做多ETF-ProShares","PSQ":"纳指反向ETF","UPRO":"三倍做多标普500ETF","DJX":"1/100道琼斯","SSO":"两倍做多标普500ETF","DXD":"道指两倍做空ETF","SPXU":"三倍做空标普500ETF","SQQQ":"纳指三倍做空ETF","OEX":"标普100","SDOW":"道指三倍做空ETF-ProShares","DDM":"道指两倍做多ETF","SPY":"标普500ETF","OEF":"标普100指数ETF-iShares","SDS":"两倍做空标普500ETF","QQQ":"纳指100ETF","DOG":"道指反向ETF",".DJI":"道琼斯","QID":"纳指两倍做空ETF",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145170778","content_text":"美联储政策制定者上周暗示，加息或比预期更快到来，这让很多投资者感到意外。\n广告美股市场闻讯下跌：标普500指数过去一周下跌1.9%，至4166.45点，创下2月份以来的最大跌幅;道琼斯工业股票平均价格指数下跌1189.52点，跌幅3.4%，至33290.08点，创下2020年10月以来的最大单周跌幅。\n投资者担心，美联储的政策转向将打击脆弱的经济复苏，并对风险资产价格造成伤害。分析师建议，尽管美联储的政策“掉头”不会突然出现，但投资者仍需将五个应对方式牢记于心。\n1、注重上市公司质量\n美联储的政策转变证实，经济正从周期的早期阶段走向中期。在早期阶段，迅猛增长是常态，而这有利于更多的投机性股票。约翰汉考克投资管理公司(John Hancock investment Management)的联席首席投资策略师艾米丽•罗兰(Emily Roland)表示，而当前的周期转变意味着，现在是时候看好股市的优质股了。\n具体来看，罗兰指出，投资者更应关注那些具有利润率更高、资产负债表强劲、自由现金流良好和股本回报率更高等特点的公司。而其中，优质股与技术板块的叠加领域尤其受分析师青睐，罗兰指出：“技术是与优质股重叠最多的领域，能够经受住更温和的增长环境。”\n2、重新开放\n在Cambiar Investors投资组合经理布莱恩•巴里斯(Brian Barish)看来，美联储上周最大的收获是承认，极端的宽松货币政策需要相对较快地结束，这是个好消息。\n巴里斯说：“很多人都认为美联储采取了某种鲁莽的姿态。”“它的政策与另一场金融危机式的衰退相一致。出乎意料的是，事实并非如此。”\n不过，尽管现在是缩减刺激措施的时候了，但更激进的美联储也让投资者感到紧张，因为有可能出现导致下一次衰退的政策错误。\n在这一背景下，巴里斯认为重新开放相关的领域将继续具备优势。具体来看，巴里斯看好Uber等打车软件，以及餐饮及零售连锁店。\n新奥尔良Villere & Co.投资组合经理桑迪•维莱尔(Sandy Villere)也认为，保持重新开放的头寸是有意义的，因为美联储加息的预期仍是在遥远的将来。“如果利率在2023年底之前都保持在低水平，那么低利率仍然需要很长一段时间，我短期内不会兑现。”\n3、小心高泡沫领域\n约翰汉考克投资管理公司策略师罗兰指出，美联储周三发出了令人困惑的复杂信号。一方面，它明确表示，最近的通胀飙升是暂时的。这是有道理的，因为通胀飙升很大程度上与供应链短缺有关。最近通货膨胀率的急剧上升也有点像海市蜃楼，因为这种比较是基于一年前疫情最严重时期暂时抑制价格。\n但另一方面，美联储提前了加息的时间表。罗兰指出“如果他们相信通胀是暂时的，为什么他们要提高加息预期?一种理论是，美联储担心市场投机过度。”\n美联储创造的过剩流动性和美国政府的财政支出，显然助长了投机领域。因此，美联储可能会对抑制导致比特币，以及GameStop和AMC等散户热门股大涨的投机行为感兴趣。\n4、削减房地产、能源和材料类股\n对普信集团(T. Rowe Price)多资产部门的资本市场策略师蒂姆•默里(Tim Murray)来说，上周美联储得到的最大启示是，它对通胀越来越警惕。他表示：“美联储不再处于自动驾驶模式。”\n这对那些从通胀中受益最大的市场领域来说是个坏消息。这意味着那些拥有随着通货膨胀而升值的房地产、能源和材料等实物资产的公司将受到打击。但默里认为，美联储不会为了应对通胀而扼杀经济增长。因此，工业类等其他周期性股票还有生命力。\n5、无需担心缩减恐慌\n紧缩计划已经提上日程，很可能在今年年底开始实施。在过去，这导致了标普500指数、纳斯达克综合指数和道琼斯工业平均指数的大规模抛售，即所谓的缩减恐慌(taper tantrums)。\n“缩减恐慌可能不会发生，”默里说。“2013年，投资者没有预料到会发生这种情况，而这一次，美联储一直在让所有人做好准备。”\n但同时，分析师也提示投资者不要回到成长股领域。纳斯达克综合指数下跌0.3%，至14030.38点，是上周唯一相对未受影响的主要股指。10年期美债收益率较低，在短期内对成长股有利，但美联储最终将开始加息，可能会对该领域估值造成打击。MKM Partners首席经济学家迈克尔•达尔达(Michael Darda)表示：“成长型股票仍需要一切正常，才能维持目前的估值水平。”","news_type":1},"isVote":1,"tweetType":1,"viewCount":1230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":167543569,"gmtCreate":1624279387051,"gmtModify":1634008518172,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"PFE 加仓","listText":"PFE 加仓","text":"PFE 加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167543569","repostId":"2145086044","repostType":2,"repost":{"id":"2145086044","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1624263746,"share":"https://www.laohu8.com/m/news/2145086044?lang=&edition=full","pubTime":"2021-06-21 16:22","market":"hk","language":"en","title":"5 Stocks To Watch For June 21, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2145086044","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li><b>Amazon.com, Inc. </b> (NASDAQ:AMZN) will remain in focus with the company’s two-day Prime shopping event beginning today. Amazon Prime Day was first observed on July 15, 2015, in celebration of the company’s 20th anniversary. Amazon shares slipped 0.1% to settle at $3,486.90 on Friday.</li>\n <li><b>Pfizer Inc </b>(NYSE:PFE) COVID-19 vaccine received provisional approval for use in the age group 12 to 15 from New Zealand's medical regulator, Stuff reported. Pfizer shares fell 0.3% to close at $38.70 on Friday.</li>\n <li><b>Orphazyme A S ADR </b>(NASDAQ:ORPH) shares dipped around 50% on Friday after the company announced it received a Complete Response Letter from the FDA for its treatment for Niemann-Pick Disease Type C and also cut its FY2021 outlook. Orphazyme shares tumbled 49.7% to close at $7.33 on Friday.</li>\n <li><b>Globus Maritime Ltd </b>(NASDAQ:GLBS) reported total comprehensive loss of $0.8 million for the first quarter, compared to $9 million loss in the year-ago period. Its voyage revenues surged to $5.2 million from $2.3 million. Globus Maritime shares gained 0.8% to close at $5.06 on Friday.</li>\n <li><b>Beigene Ltd </b>(NASDAQ:BGNE) disclosed that BRUKINSA received an approval from the China National Medical Products Administration for the treatment of adult patients with relapsed or refractory Waldenström’s macroglobulinemia. Beigene shares dropped 2.2% to settle at $321.81 on Friday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For June 21, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For June 21, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-21 16:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li><b>Amazon.com, Inc. </b> (NASDAQ:AMZN) will remain in focus with the company’s two-day Prime shopping event beginning today. Amazon Prime Day was first observed on July 15, 2015, in celebration of the company’s 20th anniversary. Amazon shares slipped 0.1% to settle at $3,486.90 on Friday.</li>\n <li><b>Pfizer Inc </b>(NYSE:PFE) COVID-19 vaccine received provisional approval for use in the age group 12 to 15 from New Zealand's medical regulator, Stuff reported. Pfizer shares fell 0.3% to close at $38.70 on Friday.</li>\n <li><b>Orphazyme A S ADR </b>(NASDAQ:ORPH) shares dipped around 50% on Friday after the company announced it received a Complete Response Letter from the FDA for its treatment for Niemann-Pick Disease Type C and also cut its FY2021 outlook. Orphazyme shares tumbled 49.7% to close at $7.33 on Friday.</li>\n <li><b>Globus Maritime Ltd </b>(NASDAQ:GLBS) reported total comprehensive loss of $0.8 million for the first quarter, compared to $9 million loss in the year-ago period. Its voyage revenues surged to $5.2 million from $2.3 million. Globus Maritime shares gained 0.8% to close at $5.06 on Friday.</li>\n <li><b>Beigene Ltd </b>(NASDAQ:BGNE) disclosed that BRUKINSA received an approval from the China National Medical Products Administration for the treatment of adult patients with relapsed or refractory Waldenström’s macroglobulinemia. Beigene shares dropped 2.2% to settle at $321.81 on Friday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","BGNE":"百济神州","PFE":"辉瑞","QNETCN":"纳斯达克中美互联网老虎指数","03086":"华夏纳指","GLBS":"Globus Maritime Limited","09086":"华夏纳指-U"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145086044","content_text":"Some of the stocks that may grab investor focus today are:\n\nAmazon.com, Inc.  (NASDAQ:AMZN) will remain in focus with the company’s two-day Prime shopping event beginning today. Amazon Prime Day was first observed on July 15, 2015, in celebration of the company’s 20th anniversary. Amazon shares slipped 0.1% to settle at $3,486.90 on Friday.\nPfizer Inc (NYSE:PFE) COVID-19 vaccine received provisional approval for use in the age group 12 to 15 from New Zealand's medical regulator, Stuff reported. Pfizer shares fell 0.3% to close at $38.70 on Friday.\nOrphazyme A S ADR (NASDAQ:ORPH) shares dipped around 50% on Friday after the company announced it received a Complete Response Letter from the FDA for its treatment for Niemann-Pick Disease Type C and also cut its FY2021 outlook. Orphazyme shares tumbled 49.7% to close at $7.33 on Friday.\nGlobus Maritime Ltd (NASDAQ:GLBS) reported total comprehensive loss of $0.8 million for the first quarter, compared to $9 million loss in the year-ago period. Its voyage revenues surged to $5.2 million from $2.3 million. Globus Maritime shares gained 0.8% to close at $5.06 on Friday.\nBeigene Ltd (NASDAQ:BGNE) disclosed that BRUKINSA received an approval from the China National Medical Products Administration for the treatment of adult patients with relapsed or refractory Waldenström’s macroglobulinemia. Beigene shares dropped 2.2% to settle at $321.81 on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":167367006,"gmtCreate":1624248014505,"gmtModify":1634008915198,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/167367006","repostId":"2145704430","repostType":4,"repost":{"id":"2145704430","kind":"highlight","weMediaInfo":{"introduction":"致力于提供最及时的财经资讯，最专业的解读分析，覆盖宏观经济、金融机构、A股市场、上市公司、投资理财等财经领域。","home_visible":1,"media_name":"券商中国","id":"9","head_image":"https://static.tigerbbs.com/d482d56459984e8c86a6a137295b3c4f"},"pubTimestamp":1624204860,"share":"https://www.laohu8.com/m/news/2145704430?lang=&edition=full","pubTime":"2021-06-21 00:01","market":"hk","language":"zh","title":"格力超级员工持股计划来了！员工可五折\"买股票\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704430","media":"券商中国","summary":"此次员工持股计划涉及多达12000人，几乎涉及公司高管、中层干部以及关键岗位的员工，是格力史上最大规模的员工持股计划，并且按照此前筹划的员工持股3%的计划，接下来或还有第二期。值得注意的是，虽然员工可以5折认购格力电器股票，但此次员工持股计划也设置了的业绩考核期。两个月后，格力电器终于公布了第一期员工持股计划（草案）。多达12000人的员工持股计划，是格力史上最大规模的员工持股计划。","content":"<p>家电龙头<a href=\"https://laohu8.com/S/000651\">格力电器</a>筹划的员工持股计划终于出炉！</p>\n<p>6月20日晚间，格力电器公布第一期员工持股计划，拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，占公司总股本的1.8%，购买价格为27.68元/股，即所回购股份均价的50%。</p>\n<p><b>此次员工持股计划涉及多达12000人，几乎涉及公司高管、中层干部以及关键岗位的员工，是格力史上最大规模的员工持股计划，并且按照此前筹划的员工持股3%的计划，接下来或还有第二期。</b></p>\n<p>其中，格力电器董事长董明珠拟认购3000万股，拟出资8.3亿元；而11992名中层干部、核心员工将认购7468.58万股，即员工人均认购6227股，人均17万元。</p>\n<p>值得注意的是，虽然员工可以5折认购格力电器股票，但此次员工持股计划也设置了的业绩考核期。业绩考核为2021年净利润为2020的110%，2022年为2020年的120%，且每股分红不低于2元。即2年后若完成考核，员工人均将赚18万元（包括2年分红1.2万元），董明珠则将收获9.5亿元（包括分红）。</p>\n<p>由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振，业绩又不及老对手美的，市值落后达2000亿元，此前还被富时罗素剔除了指数，可谓压力不小。如今，重磅推出持股计划，不知格力能否再次辉煌。</p>\n<p>格力史上最大规模员工持股计划</p>\n<p>今年4月15日，格力发布公告称，拟推出员工持股计划，此次员工持股计划拟持有的股票总数累计不超过公司股本总额的3%，单个员工拟所获股份权益对应的股票总数累计不超过公司股本总额的1%。</p>\n<p>两个月后，格力电器终于公布了第一期员工持股计划（草案）。拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，员工持股计划的存续期为3年，锁定期12个月。</p>\n<p>员工持股计划股票来源为公司回购专用账户中已回购的股份，股票规模为不超过 10836.58万股，占公司当前总股本的 1.80%。员工的认购价格为27.68元/股，为所回购股份均价的50%，5折认购也是此前市场所预期标准。</p>\n<p>此次员工持股计划的对象，包括公司董事（不含独立董事）、监事、 高级管理人员，以及公司及控股子公司经董事会认定对公司整体业绩和中长期发展具有重要作用的中层干部和核心员工。</p>\n<p>多达12000人的员工持股计划，是格力史上最大规模的员工持股计划。</p>\n<p><b>其中，格力电器董事长董明珠拟认购3000万股，占持股计划的27.68%，拟出资8.3亿元，张伟、庄培等6位高管均认购60万股，职工监事王法雯认购8万股。</b></p>\n<p>而11992名中层干部、核心员工将认购7468.58万股，占比68.92%，拟出资20.67亿元，即普通员工人均认购6227股，人均17万元。</p>\n<p><img src=\"https://static.tigerbbs.com/7c2fbb8d1fa64b5ea5d9ef74ecca584a\" tg-width=\"1080\" tg-height=\"868\" referrerpolicy=\"no-referrer\"></p>\n<p>公开信息显示，格力电器上一次大规模的股权激励还是2009年，当时大股东格力集团划转了1604.25万股格力电器股份，对格力电器6名高管以及1053名格力电器中层干部、业务骨干及控股子公司高管人员进行股权激励。当时格力电器董事长朱江洪和总裁董明珠受激励股份均为226万股。</p>\n<p>格力电器表示，推出员工持股计划的目的是进一步完善公司治理结构，建立健全公司长期、有效的激励约束机制，完善劳动者与所有者的利益共享机制，提升公司管理团队的凝聚力和公司竞争力，吸引和保留优秀的人才，为公司的持续快速发展注入新的动力。</p>\n<p>设定2年业绩考核指标，每年现金分红超100亿</p>\n<p><b>值得注意的是，虽然员工可以5折认购格力电器股票，但此次格力电器的员工持股计划也设置了严格的业绩考核期。</b></p>\n<p>业绩考核将分两期，每期可归属的比例最高为50%，并设定公司层面和个人层面的业绩考核指标，达到业绩考核指标才能获得权益。</p>\n<p>其中，第一个归属期，业绩考核指标为2021年净利润较2020 年增长不低于10%，第二个归属期，2022年净利润较2020年增长不低20%，且当年每股现金分红不低于2元或现金分红总额不低于当年净利润的50%。</p>\n<p><img src=\"https://static.tigerbbs.com/da2fafbf12a54c7fa74b35f7f3dba46b\" tg-width=\"912\" tg-height=\"201\" referrerpolicy=\"no-referrer\"></p>\n<p>值得注意的是，按照2020年格力221.8亿元的净利润计算，2021年净利润应达到243.98亿元，2022年净利润则需要达到266.16亿元，将超越2018年实现的262亿元的历史纪录。值得注意的是，去年四季度格力净利润高达85亿元，是历史上单季度最高的利润，即格力并没有“隐藏”利润、降低持股计划完成的难度。</p>\n<p>同时，这个业绩考核基本也明确了接下来2年格力现金分红的力度，即不低于2元或50%，每年现金分红将超过100亿元，这对不少投资者而言，将是一个比较确定性的利好。</p>\n<p>格力电器表示，第一个考核归属期届满，若公司业绩考核指标不达标，则递延至第二个考核归属期合并考核。而个人绩效考核则要求公司业绩达标且个人绩效考核等级为C级及以上，才可获得相应权益归属。</p>\n<p><img src=\"https://static.tigerbbs.com/1c4a5a88e2b74b58bad0ea2654ea4096\" tg-width=\"884\" tg-height=\"186\" referrerpolicy=\"no-referrer\"></p>\n<p>若第二个考核归属期届满后，公司业绩考核不达标，将由管理委员会决策处置，包括注销或由择机出售股票等，将以处置所获金额为限，返还对应持有人缴纳的原始出资额，剩余收益（如有）返还公司。</p>\n<p>即公司业绩考核指标没有完成，则所有人无法享受权益；公司业绩考核指标达到，个人业绩考核不达标，则个人无法享受该权益。</p>\n<p>格力股价能否走出阴霾？</p>\n<p>由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振。</p>\n<p>今年以来，格力股价已经跌了13.34%，市值为3229亿元，表现远不及上证指数，沪指年内上涨超2%。另外一边，美的由于去年大涨，今年跌幅达23.79%，但市值仍然领先格力电器近2000亿元。</p>\n<p><b>从业绩来看，过去五年，2016-2020年，美的的营收分别为1598亿、2419亿元、2618亿元、2794亿元、2857亿元，营收保持良好的增长态势；而格力过去五年营收分别为，1101亿元、1500亿元、2000亿元、2005亿元、1704亿元，在营收上渐渐被美的拉开了差距。</b></p>\n<p>同时，格力空调在终端与美的溢价也逐渐缩小，即两者品牌力的差距在缩小；而在国际化上，格力则不及美的，2020年美的的国际销售1210亿元，占营收比超过42%；境外收入毛利率25.45%，格力的国际销售200亿元，占营收比例不足12%，毛利率为12.13%：在多元化上，格力也不及美的，美的的生活电器，洗衣机、冰箱、电饭煲等，在多个领域成为行业龙头。</p>\n<p><b>正是因为美的过去几年的快速成长和超越，使得不少投资者看好美的，而看空格力。</b></p>\n<p>不过，2020年，虽然遭遇疫情，格力优势的线下渠道重挫，但格力坚决的进行渠道改革发力线上，董明珠更是进行多场直播带货。去年四季度实现净利润85亿元，创下历史上单季度最高的利润。2021年一季度，公司实现营收同比增长60.30%，归母净利润同比增长120.98%。</p>\n<p>东莞证券在研报中指出，2021年一季度格力业绩虽然仍未恢复至2019年同期水平，但公司业绩已出现恢复性增长。根据产业在线，格力空调2021年Q1内销量同比增长69.4%，外销量同比增长6.4%，反映出公司渠道改革和管理优化取得阶段性进展。</p>\n<p>董明珠在最新的采访中表示，坚持<a href=\"https://laohu8.com/S/300959\">线上线下</a>的销售模式，绝对不能单一走线上，也不能单一走线下。</p>\n<p><a href=\"https://laohu8.com/S/002736\">国信证券</a>指出，格力三次大额回购彰显信心，看好公司长期发展价值。同时，5月空调内销排产增速领先，销售均价迎来持续上涨。随着员工持股计划落地在即，格力的治理结构改善可期。空调主业不断扩展应用领域，在冰洗等其他家电产品上快速开拓，在<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>装备、精密模具、新能源、半导体等新兴产业实现突破，未来有望持续为公司贡献增长动力。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>格力超级员工持股计划来了！员工可五折\"买股票\"</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n格力超级员工持股计划来了！员工可五折\"买股票\"\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/9\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d482d56459984e8c86a6a137295b3c4f);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">券商中国 </p>\n<p class=\"h-time\">2021-06-21 00:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>家电龙头<a href=\"https://laohu8.com/S/000651\">格力电器</a>筹划的员工持股计划终于出炉！</p>\n<p>6月20日晚间，格力电器公布第一期员工持股计划，拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，占公司总股本的1.8%，购买价格为27.68元/股，即所回购股份均价的50%。</p>\n<p><b>此次员工持股计划涉及多达12000人，几乎涉及公司高管、中层干部以及关键岗位的员工，是格力史上最大规模的员工持股计划，并且按照此前筹划的员工持股3%的计划，接下来或还有第二期。</b></p>\n<p>其中，格力电器董事长董明珠拟认购3000万股，拟出资8.3亿元；而11992名中层干部、核心员工将认购7468.58万股，即员工人均认购6227股，人均17万元。</p>\n<p>值得注意的是，虽然员工可以5折认购格力电器股票，但此次员工持股计划也设置了的业绩考核期。业绩考核为2021年净利润为2020的110%，2022年为2020年的120%，且每股分红不低于2元。即2年后若完成考核，员工人均将赚18万元（包括2年分红1.2万元），董明珠则将收获9.5亿元（包括分红）。</p>\n<p>由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振，业绩又不及老对手美的，市值落后达2000亿元，此前还被富时罗素剔除了指数，可谓压力不小。如今，重磅推出持股计划，不知格力能否再次辉煌。</p>\n<p>格力史上最大规模员工持股计划</p>\n<p>今年4月15日，格力发布公告称，拟推出员工持股计划，此次员工持股计划拟持有的股票总数累计不超过公司股本总额的3%，单个员工拟所获股份权益对应的股票总数累计不超过公司股本总额的1%。</p>\n<p>两个月后，格力电器终于公布了第一期员工持股计划（草案）。拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，员工持股计划的存续期为3年，锁定期12个月。</p>\n<p>员工持股计划股票来源为公司回购专用账户中已回购的股份，股票规模为不超过 10836.58万股，占公司当前总股本的 1.80%。员工的认购价格为27.68元/股，为所回购股份均价的50%，5折认购也是此前市场所预期标准。</p>\n<p>此次员工持股计划的对象，包括公司董事（不含独立董事）、监事、 高级管理人员，以及公司及控股子公司经董事会认定对公司整体业绩和中长期发展具有重要作用的中层干部和核心员工。</p>\n<p>多达12000人的员工持股计划，是格力史上最大规模的员工持股计划。</p>\n<p><b>其中，格力电器董事长董明珠拟认购3000万股，占持股计划的27.68%，拟出资8.3亿元，张伟、庄培等6位高管均认购60万股，职工监事王法雯认购8万股。</b></p>\n<p>而11992名中层干部、核心员工将认购7468.58万股，占比68.92%，拟出资20.67亿元，即普通员工人均认购6227股，人均17万元。</p>\n<p><img src=\"https://static.tigerbbs.com/7c2fbb8d1fa64b5ea5d9ef74ecca584a\" tg-width=\"1080\" tg-height=\"868\" referrerpolicy=\"no-referrer\"></p>\n<p>公开信息显示，格力电器上一次大规模的股权激励还是2009年，当时大股东格力集团划转了1604.25万股格力电器股份，对格力电器6名高管以及1053名格力电器中层干部、业务骨干及控股子公司高管人员进行股权激励。当时格力电器董事长朱江洪和总裁董明珠受激励股份均为226万股。</p>\n<p>格力电器表示，推出员工持股计划的目的是进一步完善公司治理结构，建立健全公司长期、有效的激励约束机制，完善劳动者与所有者的利益共享机制，提升公司管理团队的凝聚力和公司竞争力，吸引和保留优秀的人才，为公司的持续快速发展注入新的动力。</p>\n<p>设定2年业绩考核指标，每年现金分红超100亿</p>\n<p><b>值得注意的是，虽然员工可以5折认购格力电器股票，但此次格力电器的员工持股计划也设置了严格的业绩考核期。</b></p>\n<p>业绩考核将分两期，每期可归属的比例最高为50%，并设定公司层面和个人层面的业绩考核指标，达到业绩考核指标才能获得权益。</p>\n<p>其中，第一个归属期，业绩考核指标为2021年净利润较2020 年增长不低于10%，第二个归属期，2022年净利润较2020年增长不低20%，且当年每股现金分红不低于2元或现金分红总额不低于当年净利润的50%。</p>\n<p><img src=\"https://static.tigerbbs.com/da2fafbf12a54c7fa74b35f7f3dba46b\" tg-width=\"912\" tg-height=\"201\" referrerpolicy=\"no-referrer\"></p>\n<p>值得注意的是，按照2020年格力221.8亿元的净利润计算，2021年净利润应达到243.98亿元，2022年净利润则需要达到266.16亿元，将超越2018年实现的262亿元的历史纪录。值得注意的是，去年四季度格力净利润高达85亿元，是历史上单季度最高的利润，即格力并没有“隐藏”利润、降低持股计划完成的难度。</p>\n<p>同时，这个业绩考核基本也明确了接下来2年格力现金分红的力度，即不低于2元或50%，每年现金分红将超过100亿元，这对不少投资者而言，将是一个比较确定性的利好。</p>\n<p>格力电器表示，第一个考核归属期届满，若公司业绩考核指标不达标，则递延至第二个考核归属期合并考核。而个人绩效考核则要求公司业绩达标且个人绩效考核等级为C级及以上，才可获得相应权益归属。</p>\n<p><img src=\"https://static.tigerbbs.com/1c4a5a88e2b74b58bad0ea2654ea4096\" tg-width=\"884\" tg-height=\"186\" referrerpolicy=\"no-referrer\"></p>\n<p>若第二个考核归属期届满后，公司业绩考核不达标，将由管理委员会决策处置，包括注销或由择机出售股票等，将以处置所获金额为限，返还对应持有人缴纳的原始出资额，剩余收益（如有）返还公司。</p>\n<p>即公司业绩考核指标没有完成，则所有人无法享受权益；公司业绩考核指标达到，个人业绩考核不达标，则个人无法享受该权益。</p>\n<p>格力股价能否走出阴霾？</p>\n<p>由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振。</p>\n<p>今年以来，格力股价已经跌了13.34%，市值为3229亿元，表现远不及上证指数，沪指年内上涨超2%。另外一边，美的由于去年大涨，今年跌幅达23.79%，但市值仍然领先格力电器近2000亿元。</p>\n<p><b>从业绩来看，过去五年，2016-2020年，美的的营收分别为1598亿、2419亿元、2618亿元、2794亿元、2857亿元，营收保持良好的增长态势；而格力过去五年营收分别为，1101亿元、1500亿元、2000亿元、2005亿元、1704亿元，在营收上渐渐被美的拉开了差距。</b></p>\n<p>同时，格力空调在终端与美的溢价也逐渐缩小，即两者品牌力的差距在缩小；而在国际化上，格力则不及美的，2020年美的的国际销售1210亿元，占营收比超过42%；境外收入毛利率25.45%，格力的国际销售200亿元，占营收比例不足12%，毛利率为12.13%：在多元化上，格力也不及美的，美的的生活电器，洗衣机、冰箱、电饭煲等，在多个领域成为行业龙头。</p>\n<p><b>正是因为美的过去几年的快速成长和超越，使得不少投资者看好美的，而看空格力。</b></p>\n<p>不过，2020年，虽然遭遇疫情，格力优势的线下渠道重挫，但格力坚决的进行渠道改革发力线上，董明珠更是进行多场直播带货。去年四季度实现净利润85亿元，创下历史上单季度最高的利润。2021年一季度，公司实现营收同比增长60.30%，归母净利润同比增长120.98%。</p>\n<p>东莞证券在研报中指出，2021年一季度格力业绩虽然仍未恢复至2019年同期水平，但公司业绩已出现恢复性增长。根据产业在线，格力空调2021年Q1内销量同比增长69.4%，外销量同比增长6.4%，反映出公司渠道改革和管理优化取得阶段性进展。</p>\n<p>董明珠在最新的采访中表示，坚持<a href=\"https://laohu8.com/S/300959\">线上线下</a>的销售模式，绝对不能单一走线上，也不能单一走线下。</p>\n<p><a href=\"https://laohu8.com/S/002736\">国信证券</a>指出，格力三次大额回购彰显信心，看好公司长期发展价值。同时，5月空调内销排产增速领先，销售均价迎来持续上涨。随着员工持股计划落地在即，格力的治理结构改善可期。空调主业不断扩展应用领域，在冰洗等其他家电产品上快速开拓，在<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>装备、精密模具、新能源、半导体等新兴产业实现突破，未来有望持续为公司贡献增长动力。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/0dde210ffe3142859199a0f7aae41f0a","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704430","content_text":"家电龙头格力电器筹划的员工持股计划终于出炉！\n6月20日晚间，格力电器公布第一期员工持股计划，拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，占公司总股本的1.8%，购买价格为27.68元/股，即所回购股份均价的50%。\n此次员工持股计划涉及多达12000人，几乎涉及公司高管、中层干部以及关键岗位的员工，是格力史上最大规模的员工持股计划，并且按照此前筹划的员工持股3%的计划，接下来或还有第二期。\n其中，格力电器董事长董明珠拟认购3000万股，拟出资8.3亿元；而11992名中层干部、核心员工将认购7468.58万股，即员工人均认购6227股，人均17万元。\n值得注意的是，虽然员工可以5折认购格力电器股票，但此次员工持股计划也设置了的业绩考核期。业绩考核为2021年净利润为2020的110%，2022年为2020年的120%，且每股分红不低于2元。即2年后若完成考核，员工人均将赚18万元（包括2年分红1.2万元），董明珠则将收获9.5亿元（包括分红）。\n由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振，业绩又不及老对手美的，市值落后达2000亿元，此前还被富时罗素剔除了指数，可谓压力不小。如今，重磅推出持股计划，不知格力能否再次辉煌。\n格力史上最大规模员工持股计划\n今年4月15日，格力发布公告称，拟推出员工持股计划，此次员工持股计划拟持有的股票总数累计不超过公司股本总额的3%，单个员工拟所获股份权益对应的股票总数累计不超过公司股本总额的1%。\n两个月后，格力电器终于公布了第一期员工持股计划（草案）。拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，员工持股计划的存续期为3年，锁定期12个月。\n员工持股计划股票来源为公司回购专用账户中已回购的股份，股票规模为不超过 10836.58万股，占公司当前总股本的 1.80%。员工的认购价格为27.68元/股，为所回购股份均价的50%，5折认购也是此前市场所预期标准。\n此次员工持股计划的对象，包括公司董事（不含独立董事）、监事、 高级管理人员，以及公司及控股子公司经董事会认定对公司整体业绩和中长期发展具有重要作用的中层干部和核心员工。\n多达12000人的员工持股计划，是格力史上最大规模的员工持股计划。\n其中，格力电器董事长董明珠拟认购3000万股，占持股计划的27.68%，拟出资8.3亿元，张伟、庄培等6位高管均认购60万股，职工监事王法雯认购8万股。\n而11992名中层干部、核心员工将认购7468.58万股，占比68.92%，拟出资20.67亿元，即普通员工人均认购6227股，人均17万元。\n\n公开信息显示，格力电器上一次大规模的股权激励还是2009年，当时大股东格力集团划转了1604.25万股格力电器股份，对格力电器6名高管以及1053名格力电器中层干部、业务骨干及控股子公司高管人员进行股权激励。当时格力电器董事长朱江洪和总裁董明珠受激励股份均为226万股。\n格力电器表示，推出员工持股计划的目的是进一步完善公司治理结构，建立健全公司长期、有效的激励约束机制，完善劳动者与所有者的利益共享机制，提升公司管理团队的凝聚力和公司竞争力，吸引和保留优秀的人才，为公司的持续快速发展注入新的动力。\n设定2年业绩考核指标，每年现金分红超100亿\n值得注意的是，虽然员工可以5折认购格力电器股票，但此次格力电器的员工持股计划也设置了严格的业绩考核期。\n业绩考核将分两期，每期可归属的比例最高为50%，并设定公司层面和个人层面的业绩考核指标，达到业绩考核指标才能获得权益。\n其中，第一个归属期，业绩考核指标为2021年净利润较2020 年增长不低于10%，第二个归属期，2022年净利润较2020年增长不低20%，且当年每股现金分红不低于2元或现金分红总额不低于当年净利润的50%。\n\n值得注意的是，按照2020年格力221.8亿元的净利润计算，2021年净利润应达到243.98亿元，2022年净利润则需要达到266.16亿元，将超越2018年实现的262亿元的历史纪录。值得注意的是，去年四季度格力净利润高达85亿元，是历史上单季度最高的利润，即格力并没有“隐藏”利润、降低持股计划完成的难度。\n同时，这个业绩考核基本也明确了接下来2年格力现金分红的力度，即不低于2元或50%，每年现金分红将超过100亿元，这对不少投资者而言，将是一个比较确定性的利好。\n格力电器表示，第一个考核归属期届满，若公司业绩考核指标不达标，则递延至第二个考核归属期合并考核。而个人绩效考核则要求公司业绩达标且个人绩效考核等级为C级及以上，才可获得相应权益归属。\n\n若第二个考核归属期届满后，公司业绩考核不达标，将由管理委员会决策处置，包括注销或由择机出售股票等，将以处置所获金额为限，返还对应持有人缴纳的原始出资额，剩余收益（如有）返还公司。\n即公司业绩考核指标没有完成，则所有人无法享受权益；公司业绩考核指标达到，个人业绩考核不达标，则个人无法享受该权益。\n格力股价能否走出阴霾？\n由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振。\n今年以来，格力股价已经跌了13.34%，市值为3229亿元，表现远不及上证指数，沪指年内上涨超2%。另外一边，美的由于去年大涨，今年跌幅达23.79%，但市值仍然领先格力电器近2000亿元。\n从业绩来看，过去五年，2016-2020年，美的的营收分别为1598亿、2419亿元、2618亿元、2794亿元、2857亿元，营收保持良好的增长态势；而格力过去五年营收分别为，1101亿元、1500亿元、2000亿元、2005亿元、1704亿元，在营收上渐渐被美的拉开了差距。\n同时，格力空调在终端与美的溢价也逐渐缩小，即两者品牌力的差距在缩小；而在国际化上，格力则不及美的，2020年美的的国际销售1210亿元，占营收比超过42%；境外收入毛利率25.45%，格力的国际销售200亿元，占营收比例不足12%，毛利率为12.13%：在多元化上，格力也不及美的，美的的生活电器，洗衣机、冰箱、电饭煲等，在多个领域成为行业龙头。\n正是因为美的过去几年的快速成长和超越，使得不少投资者看好美的，而看空格力。\n不过，2020年，虽然遭遇疫情，格力优势的线下渠道重挫，但格力坚决的进行渠道改革发力线上，董明珠更是进行多场直播带货。去年四季度实现净利润85亿元，创下历史上单季度最高的利润。2021年一季度，公司实现营收同比增长60.30%，归母净利润同比增长120.98%。\n东莞证券在研报中指出，2021年一季度格力业绩虽然仍未恢复至2019年同期水平，但公司业绩已出现恢复性增长。根据产业在线，格力空调2021年Q1内销量同比增长69.4%，外销量同比增长6.4%，反映出公司渠道改革和管理优化取得阶段性进展。\n董明珠在最新的采访中表示，坚持线上线下的销售模式，绝对不能单一走线上，也不能单一走线下。\n国信证券指出，格力三次大额回购彰显信心，看好公司长期发展价值。同时，5月空调内销排产增速领先，销售均价迎来持续上涨。随着员工持股计划落地在即，格力的治理结构改善可期。空调主业不断扩展应用领域，在冰洗等其他家电产品上快速开拓，在智能装备、精密模具、新能源、半导体等新兴产业实现突破，未来有望持续为公司贡献增长动力。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":167365428,"gmtCreate":1624247978864,"gmtModify":1634008916020,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167365428","repostId":"1129554767","repostType":4,"isVote":1,"tweetType":1,"viewCount":464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":162233342,"gmtCreate":1624064111486,"gmtModify":1634023390630,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"完了完了","listText":"完了完了","text":"完了完了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/162233342","repostId":"1145549454","repostType":4,"isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":166139609,"gmtCreate":1623995428801,"gmtModify":1634024386701,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"美联储慌？你慌它都还没慌啦！","listText":"美联储慌？你慌它都还没慌啦！","text":"美联储慌？你慌它都还没慌啦！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166139609","repostId":"1160559378","repostType":4,"isVote":1,"tweetType":1,"viewCount":566,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168970460,"gmtCreate":1623948202650,"gmtModify":1634025360901,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168970460","repostId":"2144743222","repostType":2,"repost":{"id":"2144743222","kind":"news","pubTimestamp":1623922740,"share":"https://www.laohu8.com/m/news/2144743222?lang=&edition=full","pubTime":"2021-06-17 17:39","market":"us","language":"zh","title":"加拿大皇家银行：将辉瑞(PFE.N)目标价从43美元升至44美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2144743222","media":"新浪财经","summary":"加拿大皇家银行：将辉瑞(PFE.N)目标价从43美元升至44美元。","content":"<html><body><article><p><a href=\"https://laohu8.com/S/RY\">加拿大皇家银行</a>：将<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE.N)目标价从43美元升至44美元。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>加拿大皇家银行：将辉瑞(PFE.N)目标价从43美元升至44美元。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n加拿大皇家银行：将辉瑞(PFE.N)目标价从43美元升至44美元。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 17:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202106171803587c159808&s=b><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>加拿大皇家银行：将辉瑞(PFE.N)目标价从43美元升至44美元。</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202106171803587c159808&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","relate_stocks":{"PFE":"辉瑞","RY":"加拿大皇家银行"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202106171803587c159808&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2144743222","content_text":"加拿大皇家银行：将辉瑞(PFE.N)目标价从43美元升至44美元。","news_type":1},"isVote":1,"tweetType":1,"viewCount":618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":163119519,"gmtCreate":1623862087731,"gmtModify":1634026809458,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"赞，加仓","listText":"赞，加仓","text":"赞，加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163119519","repostId":"2143794406","repostType":2,"repost":{"id":"2143794406","kind":"news","pubTimestamp":1623852000,"share":"https://www.laohu8.com/m/news/2143794406?lang=&edition=full","pubTime":"2021-06-16 22:00","market":"us","language":"en","title":"Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2143794406","media":"Business Wire","summary":"NEW YORK, Jun 16, 2021----Pfizer Inc.  invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, July 28, 2021. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2021 Performance Report, to be issued that morning.You can also listen to the conference call by dialing either  711-4984 in the United States and Canada or  900-3769 outside of the Un","content":"<html><body><p><b>NEW YORK, Jun 16, 2021</b>--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, July 28, 2021. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2021 Performance Report, to be issued that morning.</p>\n<p>To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call.</p>\n<p>The transcript and webcast replay of the call will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live conference call and will be accessible for at least 90 days.</p>\n<p>You can also listen to the conference call by dialing either (833) 711-4984 in the United States and Canada or (916) 900-3769 outside of the United States and Canada. The password is \"Second Quarter Earnings\".</p>\n<p><b><i>About Pfizer: Breakthroughs That Change Patients’ Lives</i></b></p>\n<p>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as <a href=\"https://laohu8.com/S/AONE\">one</a> of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at Facebook.com/Pfizer.</p>\n<p><b><i>Disclosure Notice:</i> </b><i>The webcast may include forward-looking statements about, among other things, our anticipated operating and financial performance; reorganizations; business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; manufacturing and product supply; our efforts to respond to COVID-19, including the Pfizer-BioNTech COVID-19 vaccine and our investigational protease inhibitors; and our expectations regarding the impact of COVID-19 on our business, operations and financial results that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned \"Risk Factors\" and \"Forward-Looking Information and Factors That May Affect Future Results\", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.</i></p>\n<p><i>The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.</i></p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20210616005023/en/</span></p>\n<p><b>Contacts</b></p>\n<p><span>Media Contact: </span><br/><span>Pamela Eisele </span><br/><span>+1 (212) 733-1226 </span><br/><span>Pamela.Eisele@Pfizer.com</span></p>\n<p>Investor Contact:<br/><span>Bryan Dunn </span><br/><span>+1 (212) 733-8917 </span><br/>Bryan.Dunn@Pfizer.com</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pfizer-invites-public-view-listen-140000353.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, Jun 16, 2021--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizer-invites-public-view-listen-140000353.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/yh.g95m4ZvREhK843bxnXA--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/0UCgMBhKz8nRmh44dPW.2w--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/06622586acdb12e5809a2cd641cff5b3","relate_stocks":{"00626":"大众金融控股","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/pfizer-invites-public-view-listen-140000353.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143794406","content_text":"NEW YORK, Jun 16, 2021--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, July 28, 2021. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2021 Performance Report, to be issued that morning.\nTo view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call.\nThe transcript and webcast replay of the call will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live conference call and will be accessible for at least 90 days.\nYou can also listen to the conference call by dialing either (833) 711-4984 in the United States and Canada or (916) 900-3769 outside of the United States and Canada. The password is \"Second Quarter Earnings\".\nAbout Pfizer: Breakthroughs That Change Patients’ Lives\nAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nDisclosure Notice: The webcast may include forward-looking statements about, among other things, our anticipated operating and financial performance; reorganizations; business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; manufacturing and product supply; our efforts to respond to COVID-19, including the Pfizer-BioNTech COVID-19 vaccine and our investigational protease inhibitors; and our expectations regarding the impact of COVID-19 on our business, operations and financial results that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned \"Risk Factors\" and \"Forward-Looking Information and Factors That May Affect Future Results\", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nThe forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210616005023/en/\nContacts\nMedia Contact: Pamela Eisele +1 (212) 733-1226 Pamela.Eisele@Pfizer.com\nInvestor Contact:Bryan Dunn +1 (212) 733-8917 Bryan.Dunn@Pfizer.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":563,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":160173057,"gmtCreate":1623776628679,"gmtModify":1634028359120,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"哈哈，捐到拍。","listText":"哈哈，捐到拍。","text":"哈哈，捐到拍。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/160173057","repostId":"2143734136","repostType":2,"isVote":1,"tweetType":1,"viewCount":832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":182557011,"gmtCreate":1623591921833,"gmtModify":1634031356482,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"加仓，机会来了。","listText":"加仓，机会来了。","text":"加仓，机会来了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/182557011","repostId":"2143103785","repostType":2,"repost":{"id":"2143103785","kind":"news","pubTimestamp":1623578152,"share":"https://www.laohu8.com/m/news/2143103785?lang=&edition=full","pubTime":"2021-06-13 17:55","market":"us","language":"en","title":"Science Sides with Pfizer, Despite Vaccine Fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2143103785","media":"TipRanks","summary":"Notwithstanding the horrors of the novel coronavirus pandemic, one definitive bright spot that emerged is the rapid-fire development of COVID-19 vaccines. In particular, Pfizer  and its partnership with German biotechnology firm BioNTech  stand out as the leaders, thanks to their messenger RNA-based approach.As well, lingering concerns about the solutions themselves have created a hesitancy issue, stymieing governmental efforts to contain the pandemic. According to data from the Centers for Dise","content":"<div>\n<p>Notwithstanding the horrors of the novel coronavirus pandemic, one definitive bright spot that emerged is the rapid-fire development of COVID-19 vaccines. In particular, Pfizer (PFE) and its ...</p>\n\n<a href=\"https://finance.yahoo.com/news/science-sides-pfizer-despite-vaccine-095552749.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Science Sides with Pfizer, Despite Vaccine Fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScience Sides with Pfizer, Despite Vaccine Fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 17:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/science-sides-pfizer-despite-vaccine-095552749.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Notwithstanding the horrors of the novel coronavirus pandemic, one definitive bright spot that emerged is the rapid-fire development of COVID-19 vaccines. In particular, Pfizer (PFE) and its ...</p>\n\n<a href=\"https://finance.yahoo.com/news/science-sides-pfizer-despite-vaccine-095552749.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/12MwXRJQrogeRCK9BycO4Q--~B/aD0zNjU7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/GETkTWv7PxLj6wGc.o7QBw--~B/aD0zNjU7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/911cf65266eb79097d8bac23c5654862","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/science-sides-pfizer-despite-vaccine-095552749.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143103785","content_text":"Notwithstanding the horrors of the novel coronavirus pandemic, one definitive bright spot that emerged is the rapid-fire development of COVID-19 vaccines. In particular, Pfizer (PFE) and its partnership with German biotechnology firm BioNTech (BNTX) stand out as the leaders, thanks to their messenger RNA-based approach.\nStill, it hasn’t always been smooth sailing for PFE stock, and certain headwinds have drawn concerns for investors. Most recently, President Biden supported the proposal to waive patent protections for COVID vaccines, prompting negative reactions to varying degrees for affected biotech/pharmaceutical stocks. (See Pfizer stock analysis on TipRanks)\nAs well, lingering concerns about the solutions themselves have created a hesitancy issue, stymieing governmental efforts to contain the pandemic. According to data from the Centers for Disease Control and Prevention, vaccine hesitancy is especially strong in the Sun Belt, the region where millennials generally prefer to live.\nAlthough these headwinds are concerning for the near term, over the long run, it’s very possible that the SARS-CoV-2 virus has already imparted a paradigm shift for the biotech space. That shift may bolster the case for being patiently bullish on PFE stock.\nNegative Catalysts Piling Up\nInitially, the narrative for Pfizer doesn’t seem encouraging in light of the aforementioned challenges. First, Pfizer CEO Albert Bourla warned that waiving COVID vaccine patent protections would spark a panicked run on raw materials. In turn, Bourla believes this dynamic will threaten the integrity of vaccine manufacturing.\nThis is not an issue to be taken lightly. According to Scientific American, well before the patent waiver proposal, companies were already scrambling to obtain the supplies necessary to produce mRNA vaccines. Furthermore, no one has ever produced such genetics-based vaccines at a global scale, and that imposes incredible pressure on manufacturing facilities.\nAdding a strange, almost counterbalancing threat to the raw material headwind is vaccine hesitancy. Common fears include the rapidity of COVID-19 vaccine development and distribution, as well as the “newness” of the mRNA approach.\nThough rejection of the Covid vaccine could theoretically ameliorate supply pressures, it’s not helpful in its own right. For instance, at the time of writing, the CDC reports that only 58% of the 18-years-plus demographic have received one dose, and 44% have received two doses. Fears of the vaccine ultimately affect Pfizer's business.\nSo is this a hopeless situation for PFE stock? \nFocus on the Science, Not on the Noise\nAdmittedly, the optics aren’t great. Nevertheless, the science behind Pfizer’s mRNA vaccine could win out, potentially making its shares a good long-term investment.\nPrimarily, Pfizer and rival Moderna (MRNA) enjoy emergency use authorization (EUA) for its mRNA vaccines. It’s important to note that the Food and Drug Administration has never approved such nucleic-acid-based vaccines, so the EUA is a huge deal.\nLogically, this sets up Pfizer to harness its massive resources to explore mRNA-based solutions for other diseases and conditions. Prior to Covid-19, researchers explored RNA/DNA vaccines against HIV and the Zika virus, among other viruses. Essentially, the coronavirus may spark a renaissance in biotech innovations.\nSecondly, as people gradually take the Pfizer vaccine, they will recognize that adverse reactions are few and far between. Better yet, there’s a reason for the lack of adverse reactions: according to research published by The EMBO Journal (European Molecular Biology Organization), “All mRNAs are ultimately degraded at a defined rate.”\nThis finding suggests that irrational fears of widescale mutations and other bizarre conspiracy theories are unfounded. Instead, the biotech community can deploy mRNA vaccines rapidly as a frontline response to an acute threat without apprehension over a possible impact on the human genome.\nWall Street Weighs In\nAccording to TipRanks’ analyst consensus rating, PFE stock comes in as a Hold, with 2 Buy and 10 Hold ratings assigned in the last three months.\nAs for price targets, the average analyst Pfizer price target is $44.08 per share, implying around 9.8% upside potential from current levels.\n\n\n\nA Tremendous Learning Opportunity\nMany assume that after COVID-19 finally fades -- either naturally or through herd immunity -- society will return to normal. On the other hand, that might not be the case, and many believe we should take the harsh lessons learned from this pandemic and better prepare for the next one.\nFor example, according to a Wired article earlier this year, parts of Africa provide the perfect environment for the next pandemic to arise due to “booming populations and poor health infrastructure.” Naturally, scientists are hard at work to proactively combat such threats.\nThe one source of hope that we can bank on if things go awry is the emergence of a safe, rapid and highly effective mRNA vaccine. Therefore, if we do have an outbreak of yet another mysterious disease, Pfizer, with its scientific acumen and vast resources, has a significant advantage. That makes Pfizer's stock attractive to investors, despite the headwinds it faces. \nDisclosure: Josh Enomoto does not have a position in Pfizer stock.\nDisclaimer: The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities.","news_type":1},"isVote":1,"tweetType":1,"viewCount":632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":182186256,"gmtCreate":1623557854375,"gmtModify":1634031720419,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/182186256","repostId":"2142788912","repostType":2,"repost":{"id":"2142788912","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623507814,"share":"https://www.laohu8.com/m/news/2142788912?lang=&edition=full","pubTime":"2021-06-12 22:23","market":"us","language":"en","title":"Vietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use","url":"https://stock-news.laohu8.com/highlight/detail?id=2142788912","media":"Reuters","summary":"HANOI, June 12  - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.It is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.Vietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.Vietnam is tryin","content":"<p>HANOI, June 12 (Reuters) - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.</p>\n<p>It is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.</p>\n<p>Vietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.</p>\n<p>Vietnam is trying to accelerate its vaccine procurement drive to tackle a more stubborn wave of infections, even though its overall case load and fatality numbers remain relatively low.</p>\n<p>The health ministry also said on Saturday it was in talks with an unidentified U.S. manufacturer to producer a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose vaccine with a view to producing 100 million-200 million shots per year.</p>\n<p>Vietnam, with a population of around 98 million, has recorded a total of 10,241 coronavirus cases, with 58 deaths, since the pandemic began. Its domestic inoculation started in March.</p>\n<p>At least 1.4 million people in Vietnam have had <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a COVID-19 vaccine, while 53,127 have been fully vaccinated, according to official data.</p>\n<p>(Reporting by Phuong Nguyen; Editing by Toby Chopra and Mike Harrison)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HANOI, June 12 (Reuters) - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.</p>\n<p>It is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.</p>\n<p>Vietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.</p>\n<p>Vietnam is trying to accelerate its vaccine procurement drive to tackle a more stubborn wave of infections, even though its overall case load and fatality numbers remain relatively low.</p>\n<p>The health ministry also said on Saturday it was in talks with an unidentified U.S. manufacturer to producer a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose vaccine with a view to producing 100 million-200 million shots per year.</p>\n<p>Vietnam, with a population of around 98 million, has recorded a total of 10,241 coronavirus cases, with 58 deaths, since the pandemic began. Its domestic inoculation started in March.</p>\n<p>At least 1.4 million people in Vietnam have had <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a COVID-19 vaccine, while 53,127 have been fully vaccinated, according to official data.</p>\n<p>(Reporting by Phuong Nguyen; Editing by Toby Chopra and Mike Harrison)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142788912","content_text":"HANOI, June 12 (Reuters) - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.\nIt is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.\nVietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.\nVietnam is trying to accelerate its vaccine procurement drive to tackle a more stubborn wave of infections, even though its overall case load and fatality numbers remain relatively low.\nThe health ministry also said on Saturday it was in talks with an unidentified U.S. manufacturer to producer a one-dose vaccine with a view to producing 100 million-200 million shots per year.\nVietnam, with a population of around 98 million, has recorded a total of 10,241 coronavirus cases, with 58 deaths, since the pandemic began. Its domestic inoculation started in March.\nAt least 1.4 million people in Vietnam have had one dose of a COVID-19 vaccine, while 53,127 have been fully vaccinated, according to official data.\n(Reporting by Phuong Nguyen; Editing by Toby Chopra and Mike Harrison)","news_type":1},"isVote":1,"tweetType":1,"viewCount":486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":182188461,"gmtCreate":1623557811553,"gmtModify":1634031721135,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"又休息","listText":"又休息","text":"又休息","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/182188461","repostId":"1105134625","repostType":4,"repost":{"id":"1105134625","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623140058,"share":"https://www.laohu8.com/m/news/1105134625?lang=&edition=full","pubTime":"2021-06-08 16:14","market":"sg","language":"zh","title":"提醒：端午休市安排来了！港股6月14日休市一天","url":"https://stock-news.laohu8.com/highlight/detail?id=1105134625","media":"老虎资讯综合","summary":"6月14日（周一）休市，6月15日（周二）起照常开市。美股、英股、新加坡股市照常交易。端午节，又称端阳节、龙舟节、天中节等，源于自然天象崇拜，由上古时代祭龙演变而来。因传说战国时期的楚国诗人屈原在五月五日跳汨罗江自尽，后来人们亦将端午节作为纪念屈原的节日；也有纪念伍子胥、曹娥及介子推等说法。总的来说，端午节起源于上古先民择“飞龙在天”吉日拜祭龙祖、祈福辟邪，注入夏季时令“祛病防疫\"风尚。","content":"<p>临近中国传统节日端午节假期，各主要市场休市安排如下：<img src=\"https://static.tigerbbs.com/ad358d24b10a4ecf9c9fa183f3c2ab9b\" tg-width=\"779\" tg-height=\"667\" referrerpolicy=\"no-referrer\"><b>A股：</b></p><p>6月14日（周一）休市，6月15日（周二）起照常开市。</p><p><b>港股：</b></p><p>6月14日（周一）休市，6月15日（周二）起照常开市。</p><p><b>澳股：</b></p><p>6月14日（周一）因&nbsp;Queen's Birthday&nbsp;休市，6月15日（周二）起照常开市。</p><p><b>美股、英股、新加坡股市照常交易。</b></p><p><b>沪股通、深股通：</b></p><p>6月14日（周一）不提供服务，6月15日（周二）起照常开通。</p><p><b>港股通：</b></p><p>6月14日（周一）不提供服务，6月15日（周二）起照常开通。</p><p><b>背景介绍：</b></p><p>端午节，又称端阳节、龙舟节、天中节等，源于自然天象崇拜，由上古时代祭龙演变而来。仲夏端午，苍龙七宿飞升于正南中天，处于全年最“正中”之位，即如《易经·乾卦》第五爻的爻辞曰：“飞龙在天”。其起源涵盖了古老星象文化、人文哲学等方面内容，蕴含着深邃丰厚的文化内涵，在传承发展中杂糅了多种民俗为一体，节俗内容丰富。扒龙舟与食粽是端午节的两大礼俗，这两大礼俗在中国自古传承，至今不辍。</p><p>端午节，本是上古先民创立用于拜祭龙祖、祈福辟邪的节日。因传说战国时期的楚国诗人屈原在五月五日跳汨罗江自尽，后来人们亦将端午节作为纪念屈原的节日；也有纪念伍子胥、曹娥及介子推等说法。总的来说，端午节起源于上古先民择“飞龙在天”吉日拜祭龙祖、祈福辟邪，注入夏季时令“祛病防疫\"风尚。<img src=\"https://static.tigerbbs.com/09ea6dbc4088c8bacb63a863e559c64b\" tg-width=\"640\" tg-height=\"424\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>提醒：端午休市安排来了！港股6月14日休市一天</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n提醒：端午休市安排来了！港股6月14日休市一天\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-06-08 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>临近中国传统节日端午节假期，各主要市场休市安排如下：<img src=\"https://static.tigerbbs.com/ad358d24b10a4ecf9c9fa183f3c2ab9b\" tg-width=\"779\" tg-height=\"667\" referrerpolicy=\"no-referrer\"><b>A股：</b></p><p>6月14日（周一）休市，6月15日（周二）起照常开市。</p><p><b>港股：</b></p><p>6月14日（周一）休市，6月15日（周二）起照常开市。</p><p><b>澳股：</b></p><p>6月14日（周一）因&nbsp;Queen's Birthday&nbsp;休市，6月15日（周二）起照常开市。</p><p><b>美股、英股、新加坡股市照常交易。</b></p><p><b>沪股通、深股通：</b></p><p>6月14日（周一）不提供服务，6月15日（周二）起照常开通。</p><p><b>港股通：</b></p><p>6月14日（周一）不提供服务，6月15日（周二）起照常开通。</p><p><b>背景介绍：</b></p><p>端午节，又称端阳节、龙舟节、天中节等，源于自然天象崇拜，由上古时代祭龙演变而来。仲夏端午，苍龙七宿飞升于正南中天，处于全年最“正中”之位，即如《易经·乾卦》第五爻的爻辞曰：“飞龙在天”。其起源涵盖了古老星象文化、人文哲学等方面内容，蕴含着深邃丰厚的文化内涵，在传承发展中杂糅了多种民俗为一体，节俗内容丰富。扒龙舟与食粽是端午节的两大礼俗，这两大礼俗在中国自古传承，至今不辍。</p><p>端午节，本是上古先民创立用于拜祭龙祖、祈福辟邪的节日。因传说战国时期的楚国诗人屈原在五月五日跳汨罗江自尽，后来人们亦将端午节作为纪念屈原的节日；也有纪念伍子胥、曹娥及介子推等说法。总的来说，端午节起源于上古先民择“飞龙在天”吉日拜祭龙祖、祈福辟邪，注入夏季时令“祛病防疫\"风尚。<img src=\"https://static.tigerbbs.com/09ea6dbc4088c8bacb63a863e559c64b\" tg-width=\"640\" tg-height=\"424\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/09ea6dbc4088c8bacb63a863e559c64b","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105134625","content_text":"临近中国传统节日端午节假期，各主要市场休市安排如下：A股：6月14日（周一）休市，6月15日（周二）起照常开市。港股：6月14日（周一）休市，6月15日（周二）起照常开市。澳股：6月14日（周一）因 Queen's Birthday 休市，6月15日（周二）起照常开市。美股、英股、新加坡股市照常交易。沪股通、深股通：6月14日（周一）不提供服务，6月15日（周二）起照常开通。港股通：6月14日（周一）不提供服务，6月15日（周二）起照常开通。背景介绍：端午节，又称端阳节、龙舟节、天中节等，源于自然天象崇拜，由上古时代祭龙演变而来。仲夏端午，苍龙七宿飞升于正南中天，处于全年最“正中”之位，即如《易经·乾卦》第五爻的爻辞曰：“飞龙在天”。其起源涵盖了古老星象文化、人文哲学等方面内容，蕴含着深邃丰厚的文化内涵，在传承发展中杂糅了多种民俗为一体，节俗内容丰富。扒龙舟与食粽是端午节的两大礼俗，这两大礼俗在中国自古传承，至今不辍。端午节，本是上古先民创立用于拜祭龙祖、祈福辟邪的节日。因传说战国时期的楚国诗人屈原在五月五日跳汨罗江自尽，后来人们亦将端午节作为纪念屈原的节日；也有纪念伍子胥、曹娥及介子推等说法。总的来说，端午节起源于上古先民择“飞龙在天”吉日拜祭龙祖、祈福辟邪，注入夏季时令“祛病防疫\"风尚。","news_type":1},"isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":188477749,"gmtCreate":1623460736481,"gmtModify":1634032933710,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"themes":[],"htmlText":"怎么可能，加仓","listText":"怎么可能，加仓","text":"怎么可能，加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/188477749","repostId":"2142206311","repostType":2,"repost":{"id":"2142206311","kind":"news","pubTimestamp":1623426552,"share":"https://www.laohu8.com/m/news/2142206311?lang=&edition=full","pubTime":"2021-06-11 23:49","market":"us","language":"en","title":"COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart","url":"https://stock-news.laohu8.com/highlight/detail?id=2142206311","media":"Zacks","summary":"The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention  stated that it has observed increased cases of heart inflammation in adolescents and younger adults, especially aged 12 to 24, following inoculation with authorized mRNA-based COVID-19 vaccines from Moderna MRNA, and Pfizer PFE/BioNTech BNTX.Several hundreds of cases of myocarditis and pericarditis, both conditions of heart inflammation, were reported to the U.S. government’s VAERS  following dose 1 of any mR","content":"<p>The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention (CDC) stated that it has observed increased cases of heart inflammation in adolescents and younger adults, especially aged 12 to 24, following inoculation with authorized mRNA-based COVID-19 vaccines from <b>Moderna</b> MRNA, and <b>Pfizer</b> PFE/<b>BioNTech</b> BNTX.</p><p>Several hundreds of cases of myocarditis and pericarditis, both conditions of heart inflammation, were reported to the U.S. government’s VAERS (Vaccine Adverse Event Reporting System) following dose 1 of any mRNA-based vaccine in the last two months. Please note that VAERS is a national early warning system to detect possible safety problems in U.S. licensed vaccines. The number of cases increased further after the second dose of these vaccines. Moreover, the cases occurred in higher number of younger patients following dose 2 compared to dose 1. The CDC stated that similar inflammation cases were not reported following vaccination with <b>J&amp;J</b>’s JNJ adenovirus-based COVID-19 vaccine.</p><h3>Israeli Alarm</h3><p>Per a Reuters report, the Israel’s Health Ministry raised the alarm when it reported a likely link of heart inflammation in young men vaccinated with Pfizer’s BNT162b earlier this month. Following this report, the CDC and health regulators in other countries started investigating such cases.</p><p>Although the number of reported cases is small compared to total inoculations with mRNA vaccines, they were higher than expected in the younger age groups.</p><h3>CDC Meeting</h3><p>We note that the CDC is yet to link these adverse events to mRNA vaccines and has scheduled a meeting of the Advisory Committee on Immunization Practices (ACIP) on Jun 18 to discuss and assess the heart inflammation reports. Moreover, the government authority has recommended continuation of vaccination for everyone of age 12 or older given the risk of COVID-19 illness and related complications.</p><p>However, we note that the CDC report also stated that more than 50% of heart inflammation cases were reported in the age group of 12-24 that has received only 8.8% of vaccine doses. This suggests that any adverse outcome from the ACIP meeting scheduled next week can hamper vaccination with mRNA vaccines in the adolescent patient group, and hurt prospects of these vaccine developers. However, the percentage of inflammation cases suggests that the risk from these vaccines is significantly lower than their benefits. A CDC study claims that these vaccines are 91% effective. Moreover, most patients facing inflammation issues quickly felt better following medication and rest.</p><h3>mRNA Vaccine Updates</h3><p>We remind investors that Pfizer/BioNTech’s COVID-19 vaccine received authorization for emergency use in adolescents last month from the FDA. Moderna filed for a similar authorization in the United States, Europe and Canada earlier this month.</p><p>Meanwhile, Pfizer and BioNTech have pledged two billion doses of their COVID-19 vaccines to ensure equitable access to their vaccines globally. As part of the pledge, the company plans to supply 200 million doses in 2021 and 300 million doses in the first half of 2022 to the U.S. government at not-for-profit price. The government will donate these doses to low- and lower middle-income countries and organizations that support them.</p><p>While Moderna and Pfizer carry a Zacks Rank #3 (Hold), BioNTech sports a Zacks Rank of 1 (Strong Buy). </p><p>Pfizer,&nbsp;Moderna&nbsp;fell&nbsp;over&nbsp;1%&nbsp;in&nbsp;morning&nbsp;trading.</p><p><img src=\"https://static.tigerbbs.com/4abafe1ebf6b0259e6f305a5483d4a2a\" tg-width=\"700\" tg-height=\"584\"><img src=\"https://static.tigerbbs.com/16bd6a310a9f80f7ecaf40c96b582198\" tg-width=\"700\" tg-height=\"584\"></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 23:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/covid-19-jabs-pfizer-moderna-124412703.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention (CDC) stated that it has observed increased cases of heart inflammation in adolescents and younger adults, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/covid-19-jabs-pfizer-moderna-124412703.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/i.kaShYr9WLQwJ3VXlE4CA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/aNEP4MqN0KfFI8mDHT.6JQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0bba00e006cf8b1987f4ca39d28c5938","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/covid-19-jabs-pfizer-moderna-124412703.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142206311","content_text":"The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention (CDC) stated that it has observed increased cases of heart inflammation in adolescents and younger adults, especially aged 12 to 24, following inoculation with authorized mRNA-based COVID-19 vaccines from Moderna MRNA, and Pfizer PFE/BioNTech BNTX.Several hundreds of cases of myocarditis and pericarditis, both conditions of heart inflammation, were reported to the U.S. government’s VAERS (Vaccine Adverse Event Reporting System) following dose 1 of any mRNA-based vaccine in the last two months. Please note that VAERS is a national early warning system to detect possible safety problems in U.S. licensed vaccines. The number of cases increased further after the second dose of these vaccines. Moreover, the cases occurred in higher number of younger patients following dose 2 compared to dose 1. The CDC stated that similar inflammation cases were not reported following vaccination with J&J’s JNJ adenovirus-based COVID-19 vaccine.Israeli AlarmPer a Reuters report, the Israel’s Health Ministry raised the alarm when it reported a likely link of heart inflammation in young men vaccinated with Pfizer’s BNT162b earlier this month. Following this report, the CDC and health regulators in other countries started investigating such cases.Although the number of reported cases is small compared to total inoculations with mRNA vaccines, they were higher than expected in the younger age groups.CDC MeetingWe note that the CDC is yet to link these adverse events to mRNA vaccines and has scheduled a meeting of the Advisory Committee on Immunization Practices (ACIP) on Jun 18 to discuss and assess the heart inflammation reports. Moreover, the government authority has recommended continuation of vaccination for everyone of age 12 or older given the risk of COVID-19 illness and related complications.However, we note that the CDC report also stated that more than 50% of heart inflammation cases were reported in the age group of 12-24 that has received only 8.8% of vaccine doses. This suggests that any adverse outcome from the ACIP meeting scheduled next week can hamper vaccination with mRNA vaccines in the adolescent patient group, and hurt prospects of these vaccine developers. However, the percentage of inflammation cases suggests that the risk from these vaccines is significantly lower than their benefits. A CDC study claims that these vaccines are 91% effective. Moreover, most patients facing inflammation issues quickly felt better following medication and rest.mRNA Vaccine UpdatesWe remind investors that Pfizer/BioNTech’s COVID-19 vaccine received authorization for emergency use in adolescents last month from the FDA. Moderna filed for a similar authorization in the United States, Europe and Canada earlier this month.Meanwhile, Pfizer and BioNTech have pledged two billion doses of their COVID-19 vaccines to ensure equitable access to their vaccines globally. As part of the pledge, the company plans to supply 200 million doses in 2021 and 300 million doses in the first half of 2022 to the U.S. government at not-for-profit price. The government will donate these doses to low- and lower middle-income countries and organizations that support them.While Moderna and Pfizer carry a Zacks Rank #3 (Hold), BioNTech sports a Zacks Rank of 1 (Strong Buy). Pfizer, Moderna fell over 1% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":120360036,"gmtCreate":1624300441625,"gmtModify":1634008162162,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/120360036","repostId":"2145170778","repostType":4,"repost":{"id":"2145170778","kind":"highlight","weMediaInfo":{"introduction":"中国大陆领先的金融数据、信息和软件服务企业，总部位于上海陆家嘴金融中心。","home_visible":1,"media_name":"Wind万得","id":"99","head_image":"https://static.tigerbbs.com/c71e30d1317b4a5cb20a41998e10ac68"},"pubTimestamp":1624243561,"share":"https://www.laohu8.com/m/news/2145170778?lang=&edition=full","pubTime":"2021-06-21 10:46","market":"hk","language":"zh","title":"美联储政策转向在即，这是五种应对方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2145170778","media":"Wind万得","summary":"美联储政策制定者上周暗示，加息或比预期更快到来，这让很多投资者感到意外。投资者担心，美联储的政策转向将打击脆弱的经济复苏，并对风险资产价格造成伤害。分析师建议，尽管美联储的政策“掉头”不会突然出现，但投资者仍需将五个应对方式牢记于心。美联储的政策转变证实，经济正从周期的早期阶段走向中期。","content":"<p>美联储政策制定者上周暗示，加息或比预期更快到来，这让很多投资者感到意外。</p>\n<p>广告美股市场闻讯下跌：标普500指数过去一周下跌1.9%，至4166.45点，创下2月份以来的最大跌幅;道琼斯工业股票平均价格指数下跌1189.52点，跌幅3.4%，至33290.08点，创下2020年10月以来的最大单周跌幅。</p>\n<p>投资者担心，美联储的政策转向将打击脆弱的经济复苏，并对风险资产价格造成伤害。分析师建议，尽管美联储的政策“掉头”不会突然出现，但投资者仍需将五个应对方式牢记于心。</p>\n<p><b>1、注重上市公司质量</b></p>\n<p>美联储的政策转变证实，经济正从周期的早期阶段走向中期。在早期阶段，迅猛增长是常态，而这有利于更多的投机性股票。约翰汉考克投资管理公司(John Hancock investment Management)的联席首席投资策略师艾米丽•罗兰(Emily Roland)表示，而当前的周期转变意味着，现在是时候看好股市的优质股了。</p>\n<p>具体来看，罗兰指出，投资者更应关注那些具有利润率更高、资产负债表强劲、自由现金流良好和股本回报率更高等特点的公司。而其中，优质股与技术板块的叠加领域尤其受分析师青睐，罗兰指出：“技术是与优质股重叠最多的领域，能够经受住更温和的增长环境。”</p>\n<p><b>2、重新开放</b></p>\n<p>在Cambiar Investors投资组合经理布莱恩•巴里斯(Brian Barish)看来，美联储上周最大的收获是承认，极端的宽松货币政策需要相对较快地结束，这是个好消息。</p>\n<p>巴里斯说：“很多人都认为美联储采取了某种鲁莽的姿态。”“它的政策与另一场金融危机式的衰退相一致。出乎意料的是，事实并非如此。”</p>\n<p>不过，尽管现在是缩减刺激措施的时候了，但更激进的美联储也让投资者感到紧张，因为有可能出现导致下一次衰退的政策错误。</p>\n<p>在这一背景下，巴里斯认为重新开放相关的领域将继续具备优势。具体来看，巴里斯看好Uber等打车软件，以及餐饮及零售连锁店。</p>\n<p>新奥尔良Villere &amp; Co.投资组合经理桑迪•维莱尔(Sandy Villere)也认为，保持重新开放的头寸是有意义的，因为美联储加息的预期仍是在遥远的将来。“如果利率在2023年底之前都保持在低水平，那么低利率仍然需要很长一段时间，我短期内不会兑现。”</p>\n<p><b>3、小心高泡沫领域</b></p>\n<p>约翰汉考克投资管理公司策略师罗兰指出，美联储周三发出了令人困惑的复杂信号。一方面，它明确表示，最近的通胀飙升是暂时的。这是有道理的，因为通胀飙升很大程度上与供应链短缺有关。最近通货膨胀率的急剧上升也有点像海市蜃楼，因为这种比较是基于一年前疫情最严重时期暂时抑制价格。</p>\n<p>但另一方面，美联储提前了加息的时间表。罗兰指出“如果他们相信通胀是暂时的，为什么他们要提高加息预期?一种理论是，美联储担心市场投机过度。”</p>\n<p>美联储创造的过剩流动性和美国政府的财政支出，显然助长了投机领域。因此，美联储可能会对抑制导致比特币，以及GameStop和AMC等散户热门股大涨的投机行为感兴趣。</p>\n<p><b>4、削减房地产、能源和材料类股</b></p>\n<p>对普信集团(T. Rowe Price)多资产部门的资本市场策略师蒂姆•默里(Tim Murray)来说，上周美联储得到的最大启示是，它对通胀越来越警惕。他表示：“美联储不再处于自动驾驶模式。”</p>\n<p>这对那些从通胀中受益最大的市场领域来说是个坏消息。这意味着那些拥有随着通货膨胀而升值的房地产、能源和材料等实物资产的公司将受到打击。但默里认为，美联储不会为了应对通胀而扼杀经济增长。因此，工业类等其他周期性股票还有生命力。</p>\n<p><b>5、无需担心缩减恐慌</b></p>\n<p>紧缩计划已经提上日程，很可能在今年年底开始实施。在过去，这导致了标普500指数、纳斯达克综合指数和道琼斯工业平均指数的大规模抛售，即所谓的缩减恐慌(taper tantrums)。</p>\n<p>“缩减恐慌可能不会发生，”默里说。“2013年，投资者没有预料到会发生这种情况，而这一次，美联储一直在让所有人做好准备。”</p>\n<p>但同时，分析师也提示投资者不要回到成长股领域。纳斯达克综合指数下跌0.3%，至14030.38点，是上周唯一相对未受影响的主要股指。10年期美债收益率较低，在短期内对成长股有利，但美联储最终将开始加息，可能会对该领域估值造成打击。MKM Partners首席经济学家迈克尔•达尔达(Michael Darda)表示：“成长型股票仍需要一切正常，才能维持目前的估值水平。”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美联储政策转向在即，这是五种应对方式</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美联储政策转向在即，这是五种应对方式\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/99\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/c71e30d1317b4a5cb20a41998e10ac68);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Wind万得 </p>\n<p class=\"h-time\">2021-06-21 10:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>美联储政策制定者上周暗示，加息或比预期更快到来，这让很多投资者感到意外。</p>\n<p>广告美股市场闻讯下跌：标普500指数过去一周下跌1.9%，至4166.45点，创下2月份以来的最大跌幅;道琼斯工业股票平均价格指数下跌1189.52点，跌幅3.4%，至33290.08点，创下2020年10月以来的最大单周跌幅。</p>\n<p>投资者担心，美联储的政策转向将打击脆弱的经济复苏，并对风险资产价格造成伤害。分析师建议，尽管美联储的政策“掉头”不会突然出现，但投资者仍需将五个应对方式牢记于心。</p>\n<p><b>1、注重上市公司质量</b></p>\n<p>美联储的政策转变证实，经济正从周期的早期阶段走向中期。在早期阶段，迅猛增长是常态，而这有利于更多的投机性股票。约翰汉考克投资管理公司(John Hancock investment Management)的联席首席投资策略师艾米丽•罗兰(Emily Roland)表示，而当前的周期转变意味着，现在是时候看好股市的优质股了。</p>\n<p>具体来看，罗兰指出，投资者更应关注那些具有利润率更高、资产负债表强劲、自由现金流良好和股本回报率更高等特点的公司。而其中，优质股与技术板块的叠加领域尤其受分析师青睐，罗兰指出：“技术是与优质股重叠最多的领域，能够经受住更温和的增长环境。”</p>\n<p><b>2、重新开放</b></p>\n<p>在Cambiar Investors投资组合经理布莱恩•巴里斯(Brian Barish)看来，美联储上周最大的收获是承认，极端的宽松货币政策需要相对较快地结束，这是个好消息。</p>\n<p>巴里斯说：“很多人都认为美联储采取了某种鲁莽的姿态。”“它的政策与另一场金融危机式的衰退相一致。出乎意料的是，事实并非如此。”</p>\n<p>不过，尽管现在是缩减刺激措施的时候了，但更激进的美联储也让投资者感到紧张，因为有可能出现导致下一次衰退的政策错误。</p>\n<p>在这一背景下，巴里斯认为重新开放相关的领域将继续具备优势。具体来看，巴里斯看好Uber等打车软件，以及餐饮及零售连锁店。</p>\n<p>新奥尔良Villere &amp; Co.投资组合经理桑迪•维莱尔(Sandy Villere)也认为，保持重新开放的头寸是有意义的，因为美联储加息的预期仍是在遥远的将来。“如果利率在2023年底之前都保持在低水平，那么低利率仍然需要很长一段时间，我短期内不会兑现。”</p>\n<p><b>3、小心高泡沫领域</b></p>\n<p>约翰汉考克投资管理公司策略师罗兰指出，美联储周三发出了令人困惑的复杂信号。一方面，它明确表示，最近的通胀飙升是暂时的。这是有道理的，因为通胀飙升很大程度上与供应链短缺有关。最近通货膨胀率的急剧上升也有点像海市蜃楼，因为这种比较是基于一年前疫情最严重时期暂时抑制价格。</p>\n<p>但另一方面，美联储提前了加息的时间表。罗兰指出“如果他们相信通胀是暂时的，为什么他们要提高加息预期?一种理论是，美联储担心市场投机过度。”</p>\n<p>美联储创造的过剩流动性和美国政府的财政支出，显然助长了投机领域。因此，美联储可能会对抑制导致比特币，以及GameStop和AMC等散户热门股大涨的投机行为感兴趣。</p>\n<p><b>4、削减房地产、能源和材料类股</b></p>\n<p>对普信集团(T. Rowe Price)多资产部门的资本市场策略师蒂姆•默里(Tim Murray)来说，上周美联储得到的最大启示是，它对通胀越来越警惕。他表示：“美联储不再处于自动驾驶模式。”</p>\n<p>这对那些从通胀中受益最大的市场领域来说是个坏消息。这意味着那些拥有随着通货膨胀而升值的房地产、能源和材料等实物资产的公司将受到打击。但默里认为，美联储不会为了应对通胀而扼杀经济增长。因此，工业类等其他周期性股票还有生命力。</p>\n<p><b>5、无需担心缩减恐慌</b></p>\n<p>紧缩计划已经提上日程，很可能在今年年底开始实施。在过去，这导致了标普500指数、纳斯达克综合指数和道琼斯工业平均指数的大规模抛售，即所谓的缩减恐慌(taper tantrums)。</p>\n<p>“缩减恐慌可能不会发生，”默里说。“2013年，投资者没有预料到会发生这种情况，而这一次，美联储一直在让所有人做好准备。”</p>\n<p>但同时，分析师也提示投资者不要回到成长股领域。纳斯达克综合指数下跌0.3%，至14030.38点，是上周唯一相对未受影响的主要股指。10年期美债收益率较低，在短期内对成长股有利，但美联储最终将开始加息，可能会对该领域估值造成打击。MKM Partners首席经济学家迈克尔•达尔达(Michael Darda)表示：“成长型股票仍需要一切正常，才能维持目前的估值水平。”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/211b73624a3397dc62c448ac2ccbb4c7","relate_stocks":{"161125":"标普500","513500":"标普500ETF","TQQQ":"纳指三倍做多ETF","SH":"标普500反向ETF","IVV":"标普500指数ETF","QLD":"纳指两倍做多ETF","UDOW":"道指三倍做多ETF-ProShares","PSQ":"纳指反向ETF","UPRO":"三倍做多标普500ETF","DJX":"1/100道琼斯","SSO":"两倍做多标普500ETF","DXD":"道指两倍做空ETF","SPXU":"三倍做空标普500ETF","SQQQ":"纳指三倍做空ETF","OEX":"标普100","SDOW":"道指三倍做空ETF-ProShares","DDM":"道指两倍做多ETF","SPY":"标普500ETF","OEF":"标普100指数ETF-iShares","SDS":"两倍做空标普500ETF","QQQ":"纳指100ETF","DOG":"道指反向ETF",".DJI":"道琼斯","QID":"纳指两倍做空ETF",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145170778","content_text":"美联储政策制定者上周暗示，加息或比预期更快到来，这让很多投资者感到意外。\n广告美股市场闻讯下跌：标普500指数过去一周下跌1.9%，至4166.45点，创下2月份以来的最大跌幅;道琼斯工业股票平均价格指数下跌1189.52点，跌幅3.4%，至33290.08点，创下2020年10月以来的最大单周跌幅。\n投资者担心，美联储的政策转向将打击脆弱的经济复苏，并对风险资产价格造成伤害。分析师建议，尽管美联储的政策“掉头”不会突然出现，但投资者仍需将五个应对方式牢记于心。\n1、注重上市公司质量\n美联储的政策转变证实，经济正从周期的早期阶段走向中期。在早期阶段，迅猛增长是常态，而这有利于更多的投机性股票。约翰汉考克投资管理公司(John Hancock investment Management)的联席首席投资策略师艾米丽•罗兰(Emily Roland)表示，而当前的周期转变意味着，现在是时候看好股市的优质股了。\n具体来看，罗兰指出，投资者更应关注那些具有利润率更高、资产负债表强劲、自由现金流良好和股本回报率更高等特点的公司。而其中，优质股与技术板块的叠加领域尤其受分析师青睐，罗兰指出：“技术是与优质股重叠最多的领域，能够经受住更温和的增长环境。”\n2、重新开放\n在Cambiar Investors投资组合经理布莱恩•巴里斯(Brian Barish)看来，美联储上周最大的收获是承认，极端的宽松货币政策需要相对较快地结束，这是个好消息。\n巴里斯说：“很多人都认为美联储采取了某种鲁莽的姿态。”“它的政策与另一场金融危机式的衰退相一致。出乎意料的是，事实并非如此。”\n不过，尽管现在是缩减刺激措施的时候了，但更激进的美联储也让投资者感到紧张，因为有可能出现导致下一次衰退的政策错误。\n在这一背景下，巴里斯认为重新开放相关的领域将继续具备优势。具体来看，巴里斯看好Uber等打车软件，以及餐饮及零售连锁店。\n新奥尔良Villere & Co.投资组合经理桑迪•维莱尔(Sandy Villere)也认为，保持重新开放的头寸是有意义的，因为美联储加息的预期仍是在遥远的将来。“如果利率在2023年底之前都保持在低水平，那么低利率仍然需要很长一段时间，我短期内不会兑现。”\n3、小心高泡沫领域\n约翰汉考克投资管理公司策略师罗兰指出，美联储周三发出了令人困惑的复杂信号。一方面，它明确表示，最近的通胀飙升是暂时的。这是有道理的，因为通胀飙升很大程度上与供应链短缺有关。最近通货膨胀率的急剧上升也有点像海市蜃楼，因为这种比较是基于一年前疫情最严重时期暂时抑制价格。\n但另一方面，美联储提前了加息的时间表。罗兰指出“如果他们相信通胀是暂时的，为什么他们要提高加息预期?一种理论是，美联储担心市场投机过度。”\n美联储创造的过剩流动性和美国政府的财政支出，显然助长了投机领域。因此，美联储可能会对抑制导致比特币，以及GameStop和AMC等散户热门股大涨的投机行为感兴趣。\n4、削减房地产、能源和材料类股\n对普信集团(T. Rowe Price)多资产部门的资本市场策略师蒂姆•默里(Tim Murray)来说，上周美联储得到的最大启示是，它对通胀越来越警惕。他表示：“美联储不再处于自动驾驶模式。”\n这对那些从通胀中受益最大的市场领域来说是个坏消息。这意味着那些拥有随着通货膨胀而升值的房地产、能源和材料等实物资产的公司将受到打击。但默里认为，美联储不会为了应对通胀而扼杀经济增长。因此，工业类等其他周期性股票还有生命力。\n5、无需担心缩减恐慌\n紧缩计划已经提上日程，很可能在今年年底开始实施。在过去，这导致了标普500指数、纳斯达克综合指数和道琼斯工业平均指数的大规模抛售，即所谓的缩减恐慌(taper tantrums)。\n“缩减恐慌可能不会发生，”默里说。“2013年，投资者没有预料到会发生这种情况，而这一次，美联储一直在让所有人做好准备。”\n但同时，分析师也提示投资者不要回到成长股领域。纳斯达克综合指数下跌0.3%，至14030.38点，是上周唯一相对未受影响的主要股指。10年期美债收益率较低，在短期内对成长股有利，但美联储最终将开始加息，可能会对该领域估值造成打击。MKM Partners首席经济学家迈克尔•达尔达(Michael Darda)表示：“成长型股票仍需要一切正常，才能维持目前的估值水平。”","news_type":1},"isVote":1,"tweetType":1,"viewCount":1230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":117931601,"gmtCreate":1623112842203,"gmtModify":1634036862592,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/117931601","repostId":"1131814869","repostType":4,"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":188477749,"gmtCreate":1623460736481,"gmtModify":1634032933710,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"怎么可能，加仓","listText":"怎么可能，加仓","text":"怎么可能，加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/188477749","repostId":"2142206311","repostType":2,"repost":{"id":"2142206311","kind":"news","pubTimestamp":1623426552,"share":"https://www.laohu8.com/m/news/2142206311?lang=&edition=full","pubTime":"2021-06-11 23:49","market":"us","language":"en","title":"COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart","url":"https://stock-news.laohu8.com/highlight/detail?id=2142206311","media":"Zacks","summary":"The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention  stated that it has observed increased cases of heart inflammation in adolescents and younger adults, especially aged 12 to 24, following inoculation with authorized mRNA-based COVID-19 vaccines from Moderna MRNA, and Pfizer PFE/BioNTech BNTX.Several hundreds of cases of myocarditis and pericarditis, both conditions of heart inflammation, were reported to the U.S. government’s VAERS  following dose 1 of any mR","content":"<p>The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention (CDC) stated that it has observed increased cases of heart inflammation in adolescents and younger adults, especially aged 12 to 24, following inoculation with authorized mRNA-based COVID-19 vaccines from <b>Moderna</b> MRNA, and <b>Pfizer</b> PFE/<b>BioNTech</b> BNTX.</p><p>Several hundreds of cases of myocarditis and pericarditis, both conditions of heart inflammation, were reported to the U.S. government’s VAERS (Vaccine Adverse Event Reporting System) following dose 1 of any mRNA-based vaccine in the last two months. Please note that VAERS is a national early warning system to detect possible safety problems in U.S. licensed vaccines. The number of cases increased further after the second dose of these vaccines. Moreover, the cases occurred in higher number of younger patients following dose 2 compared to dose 1. The CDC stated that similar inflammation cases were not reported following vaccination with <b>J&amp;J</b>’s JNJ adenovirus-based COVID-19 vaccine.</p><h3>Israeli Alarm</h3><p>Per a Reuters report, the Israel’s Health Ministry raised the alarm when it reported a likely link of heart inflammation in young men vaccinated with Pfizer’s BNT162b earlier this month. Following this report, the CDC and health regulators in other countries started investigating such cases.</p><p>Although the number of reported cases is small compared to total inoculations with mRNA vaccines, they were higher than expected in the younger age groups.</p><h3>CDC Meeting</h3><p>We note that the CDC is yet to link these adverse events to mRNA vaccines and has scheduled a meeting of the Advisory Committee on Immunization Practices (ACIP) on Jun 18 to discuss and assess the heart inflammation reports. Moreover, the government authority has recommended continuation of vaccination for everyone of age 12 or older given the risk of COVID-19 illness and related complications.</p><p>However, we note that the CDC report also stated that more than 50% of heart inflammation cases were reported in the age group of 12-24 that has received only 8.8% of vaccine doses. This suggests that any adverse outcome from the ACIP meeting scheduled next week can hamper vaccination with mRNA vaccines in the adolescent patient group, and hurt prospects of these vaccine developers. However, the percentage of inflammation cases suggests that the risk from these vaccines is significantly lower than their benefits. A CDC study claims that these vaccines are 91% effective. Moreover, most patients facing inflammation issues quickly felt better following medication and rest.</p><h3>mRNA Vaccine Updates</h3><p>We remind investors that Pfizer/BioNTech’s COVID-19 vaccine received authorization for emergency use in adolescents last month from the FDA. Moderna filed for a similar authorization in the United States, Europe and Canada earlier this month.</p><p>Meanwhile, Pfizer and BioNTech have pledged two billion doses of their COVID-19 vaccines to ensure equitable access to their vaccines globally. As part of the pledge, the company plans to supply 200 million doses in 2021 and 300 million doses in the first half of 2022 to the U.S. government at not-for-profit price. The government will donate these doses to low- and lower middle-income countries and organizations that support them.</p><p>While Moderna and Pfizer carry a Zacks Rank #3 (Hold), BioNTech sports a Zacks Rank of 1 (Strong Buy). </p><p>Pfizer,&nbsp;Moderna&nbsp;fell&nbsp;over&nbsp;1%&nbsp;in&nbsp;morning&nbsp;trading.</p><p><img src=\"https://static.tigerbbs.com/4abafe1ebf6b0259e6f305a5483d4a2a\" tg-width=\"700\" tg-height=\"584\"><img src=\"https://static.tigerbbs.com/16bd6a310a9f80f7ecaf40c96b582198\" tg-width=\"700\" tg-height=\"584\"></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 23:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/covid-19-jabs-pfizer-moderna-124412703.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention (CDC) stated that it has observed increased cases of heart inflammation in adolescents and younger adults, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/covid-19-jabs-pfizer-moderna-124412703.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/i.kaShYr9WLQwJ3VXlE4CA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/aNEP4MqN0KfFI8mDHT.6JQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0bba00e006cf8b1987f4ca39d28c5938","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/covid-19-jabs-pfizer-moderna-124412703.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142206311","content_text":"The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention (CDC) stated that it has observed increased cases of heart inflammation in adolescents and younger adults, especially aged 12 to 24, following inoculation with authorized mRNA-based COVID-19 vaccines from Moderna MRNA, and Pfizer PFE/BioNTech BNTX.Several hundreds of cases of myocarditis and pericarditis, both conditions of heart inflammation, were reported to the U.S. government’s VAERS (Vaccine Adverse Event Reporting System) following dose 1 of any mRNA-based vaccine in the last two months. Please note that VAERS is a national early warning system to detect possible safety problems in U.S. licensed vaccines. The number of cases increased further after the second dose of these vaccines. Moreover, the cases occurred in higher number of younger patients following dose 2 compared to dose 1. The CDC stated that similar inflammation cases were not reported following vaccination with J&J’s JNJ adenovirus-based COVID-19 vaccine.Israeli AlarmPer a Reuters report, the Israel’s Health Ministry raised the alarm when it reported a likely link of heart inflammation in young men vaccinated with Pfizer’s BNT162b earlier this month. Following this report, the CDC and health regulators in other countries started investigating such cases.Although the number of reported cases is small compared to total inoculations with mRNA vaccines, they were higher than expected in the younger age groups.CDC MeetingWe note that the CDC is yet to link these adverse events to mRNA vaccines and has scheduled a meeting of the Advisory Committee on Immunization Practices (ACIP) on Jun 18 to discuss and assess the heart inflammation reports. Moreover, the government authority has recommended continuation of vaccination for everyone of age 12 or older given the risk of COVID-19 illness and related complications.However, we note that the CDC report also stated that more than 50% of heart inflammation cases were reported in the age group of 12-24 that has received only 8.8% of vaccine doses. This suggests that any adverse outcome from the ACIP meeting scheduled next week can hamper vaccination with mRNA vaccines in the adolescent patient group, and hurt prospects of these vaccine developers. However, the percentage of inflammation cases suggests that the risk from these vaccines is significantly lower than their benefits. A CDC study claims that these vaccines are 91% effective. Moreover, most patients facing inflammation issues quickly felt better following medication and rest.mRNA Vaccine UpdatesWe remind investors that Pfizer/BioNTech’s COVID-19 vaccine received authorization for emergency use in adolescents last month from the FDA. Moderna filed for a similar authorization in the United States, Europe and Canada earlier this month.Meanwhile, Pfizer and BioNTech have pledged two billion doses of their COVID-19 vaccines to ensure equitable access to their vaccines globally. As part of the pledge, the company plans to supply 200 million doses in 2021 and 300 million doses in the first half of 2022 to the U.S. government at not-for-profit price. The government will donate these doses to low- and lower middle-income countries and organizations that support them.While Moderna and Pfizer carry a Zacks Rank #3 (Hold), BioNTech sports a Zacks Rank of 1 (Strong Buy). Pfizer, Moderna fell over 1% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":123507614,"gmtCreate":1624427907138,"gmtModify":1634006244546,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"加仓，辉瑞。","listText":"加仓，辉瑞。","text":"加仓，辉瑞。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/123507614","repostId":"2145062155","repostType":2,"isVote":1,"tweetType":1,"viewCount":1584,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":131182307,"gmtCreate":1621835900609,"gmtModify":1634186202542,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"请问辉瑞 5/6/21派股息，那它的 16/7/21的期权价或行权价会受影响吗？","listText":"请问辉瑞 5/6/21派股息，那它的 16/7/21的期权价或行权价会受影响吗？","text":"请问辉瑞 5/6/21派股息，那它的 16/7/21的期权价或行权价会受影响吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/131182307","repostId":"2137840401","repostType":2,"isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":145465294,"gmtCreate":1626238674318,"gmtModify":1633928717796,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"唱歌不会啦，跳舞可能！","listText":"唱歌不会啦，跳舞可能！","text":"唱歌不会啦，跳舞可能！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145465294","repostId":"2151550481","repostType":2,"repost":{"id":"2151550481","kind":"highlight","pubTimestamp":1626231600,"share":"https://www.laohu8.com/m/news/2151550481?lang=&edition=full","pubTime":"2021-07-14 11:00","market":"us","language":"en","title":"Why the CDC and FDA Just Slapped Down Pfizer and Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2151550481","media":"Motley Fool","summary":"There's a bit of a brouhaha over booster doses.","content":"<p><b>Pfizer</b> (NYSE:PFE)&nbsp;and&nbsp;<b>Moderna</b> (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control &amp; Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The FDA granted quick approvals to both drugmakers' COVID-19 vaccines last December. The CDC has encouraged Americans to receive both vaccines.</p>\n<p>However, some might now think that the honeymoon is over. Pfizer and Moderna have recently expressed support for booster doses. The CDC and FDA issued a joint public statement last week that appeared to contradict this view. Here's why the two federal agencies just slapped down Pfizer and Moderna.</p>\n<p><img src=\"https://static.tigerbbs.com/9282ceea65d6d87d5e9d88017233aa2a\" tg-width=\"700\" tg-height=\"408\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>A quick and forceful response</h3>\n<p>On July 8, Pfizer chief scientific officer Mikael Dolsten told Reuters in an interview that his company and its partner, <b>BioNTech</b> (NASDAQ:BNTX), plan to soon file for U.S. and European emergency use authorizations (EUA) for a third booster dose. In a separate interview on the same day with CTV News Channel, Moderna co-founder Derrick Rossi said that \"a booster is almost certainly the way.\"</p>\n<p>Rossi doesn't serve on Moderna's management team or board of directors,&nbsp;so his comments didn't represent the biotech's official stance. However, Moderna CEO Stephane Bancel stated in the company's first-quarter conference call: \"We have said for right now that we believe booster shots will be needed as we believe that the virus is not going away.\"</p>\n<p>Later in the day on July 8, the CDC and FDA issued a joint statement on vaccine boosters. The agencies stated:</p>\n<blockquote>\n Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively. We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed.\n</blockquote>\n<p>The CDC-FDA statement appeared to be a direct slap-down -- especially to Pfizer. But why would the agencies respond so quickly and forcefully? The main reason is probably that they don't want to worry Americans who have already been vaccinated, nor give any reason for unvaccinated individuals to delay receiving a vaccine.</p>\n<p>However, I suspect that the FDA, in particular, also had another motivation. The agency doesn't want to be viewed as having too cozy of a relationship with any drugmaker. It has been heavily criticized for the process followed in approving <b>Biogen</b>'s Alzheimer's disease drug Aduhelm. FDA Commissioner Dr. Janet Woodcock even requested an independent investigation into interactions between the agency's staff and Biogen during the review process for the drug.</p>\n<h3>Reconciliable differences</h3>\n<p>Despite the seeming squabble, I don't think that the CDC and the FDA are really in direct opposition to what Pfizer and Moderna have said. There are several similarities between their public statements.</p>\n<p>Both sides agree that the currently available messenger RNA (mRNA) vaccines remain effective at preventing COVID-19. Both also look to data to form their views.</p>\n<p>Pfizer and BioNTech stated last week that their initial data indicates that a third booster dose generates significantly higher antibody levels than only two doses -- five to 10 times more. The CDC and FDA haven't seen this data yet, though. Pfizer and BioNTech expect to submit the data to the FDA as well as to the European Medicines Agency and other regulatory authorities within the next few weeks.</p>\n<p>The differences between the CDC-FDA view and Pfizer-BioNTech-Moderna perspective appear to be mainly related to timing. The drugmakers believe they've seen enough data to know now that booster doses will be needed, while the federal agencies think they need to see more data but aren't ruling out the potential need for booster doses.</p>\n<h3>Why all of this matters</h3>\n<p>Clearly, Pfizer, BioNTech, and Moderna benefit financially if booster doses are needed. The more COVID-19 vaccine doses are required, the higher the companies' sales will be and the better the vaccine stocks will likely perform.</p>\n<p>Government agencies aren't (or at least shouldn't be) concerned with how much money any of these companies make. However, they are responsible for promoting public health. If booster doses are what it takes to effectively fight the spread of COVID-19, they'll be authorized.</p>\n<p>My hunch is that the recent real-world data from Israel gives a good clue as to what will happen going forward. That data found only 64% efficacy of the Pfizer-BioNTech vaccine against COVID-19 overall, down from 94% a month earlier, primarily because of the spread of the delta variant. If a third booster dose can get efficacy closer to the initial level, it would be shocking if authorizations aren't granted.</p>\n<p>Pfizer, Moderna, the CDC, and the FDA might not always be in harmony. However, I predict they'll soon be singing from the same page when it comes to the need for booster doses.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why the CDC and FDA Just Slapped Down Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy the CDC and FDA Just Slapped Down Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151550481","content_text":"Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The FDA granted quick approvals to both drugmakers' COVID-19 vaccines last December. The CDC has encouraged Americans to receive both vaccines.\nHowever, some might now think that the honeymoon is over. Pfizer and Moderna have recently expressed support for booster doses. The CDC and FDA issued a joint public statement last week that appeared to contradict this view. Here's why the two federal agencies just slapped down Pfizer and Moderna.\n\nImage source: Getty Images.\nA quick and forceful response\nOn July 8, Pfizer chief scientific officer Mikael Dolsten told Reuters in an interview that his company and its partner, BioNTech (NASDAQ:BNTX), plan to soon file for U.S. and European emergency use authorizations (EUA) for a third booster dose. In a separate interview on the same day with CTV News Channel, Moderna co-founder Derrick Rossi said that \"a booster is almost certainly the way.\"\nRossi doesn't serve on Moderna's management team or board of directors, so his comments didn't represent the biotech's official stance. However, Moderna CEO Stephane Bancel stated in the company's first-quarter conference call: \"We have said for right now that we believe booster shots will be needed as we believe that the virus is not going away.\"\nLater in the day on July 8, the CDC and FDA issued a joint statement on vaccine boosters. The agencies stated:\n\n Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively. We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed.\n\nThe CDC-FDA statement appeared to be a direct slap-down -- especially to Pfizer. But why would the agencies respond so quickly and forcefully? The main reason is probably that they don't want to worry Americans who have already been vaccinated, nor give any reason for unvaccinated individuals to delay receiving a vaccine.\nHowever, I suspect that the FDA, in particular, also had another motivation. The agency doesn't want to be viewed as having too cozy of a relationship with any drugmaker. It has been heavily criticized for the process followed in approving Biogen's Alzheimer's disease drug Aduhelm. FDA Commissioner Dr. Janet Woodcock even requested an independent investigation into interactions between the agency's staff and Biogen during the review process for the drug.\nReconciliable differences\nDespite the seeming squabble, I don't think that the CDC and the FDA are really in direct opposition to what Pfizer and Moderna have said. There are several similarities between their public statements.\nBoth sides agree that the currently available messenger RNA (mRNA) vaccines remain effective at preventing COVID-19. Both also look to data to form their views.\nPfizer and BioNTech stated last week that their initial data indicates that a third booster dose generates significantly higher antibody levels than only two doses -- five to 10 times more. The CDC and FDA haven't seen this data yet, though. Pfizer and BioNTech expect to submit the data to the FDA as well as to the European Medicines Agency and other regulatory authorities within the next few weeks.\nThe differences between the CDC-FDA view and Pfizer-BioNTech-Moderna perspective appear to be mainly related to timing. The drugmakers believe they've seen enough data to know now that booster doses will be needed, while the federal agencies think they need to see more data but aren't ruling out the potential need for booster doses.\nWhy all of this matters\nClearly, Pfizer, BioNTech, and Moderna benefit financially if booster doses are needed. The more COVID-19 vaccine doses are required, the higher the companies' sales will be and the better the vaccine stocks will likely perform.\nGovernment agencies aren't (or at least shouldn't be) concerned with how much money any of these companies make. However, they are responsible for promoting public health. If booster doses are what it takes to effectively fight the spread of COVID-19, they'll be authorized.\nMy hunch is that the recent real-world data from Israel gives a good clue as to what will happen going forward. That data found only 64% efficacy of the Pfizer-BioNTech vaccine against COVID-19 overall, down from 94% a month earlier, primarily because of the spread of the delta variant. If a third booster dose can get efficacy closer to the initial level, it would be shocking if authorizations aren't granted.\nPfizer, Moderna, the CDC, and the FDA might not always be in harmony. However, I predict they'll soon be singing from the same page when it comes to the need for booster doses.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":355051051,"gmtCreate":1617017648473,"gmtModify":1634523124452,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"跟就对了","listText":"跟就对了","text":"跟就对了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/355051051","repostId":"2123237957","repostType":4,"repost":{"id":"2123237957","kind":"news","weMediaInfo":{"introduction":"中国大陆领先的金融数据、信息和软件服务企业，总部位于上海陆家嘴金融中心。","home_visible":1,"media_name":"Wind万得","id":"99","head_image":"https://static.tigerbbs.com/c71e30d1317b4a5cb20a41998e10ac68"},"pubTimestamp":1617017582,"share":"https://www.laohu8.com/m/news/2123237957?lang=&edition=full","pubTime":"2021-03-29 19:33","market":"us","language":"zh","title":"ARK旗下明星基金产品面临洗牌转变","url":"https://stock-news.laohu8.com/highlight/detail?id=2123237957","media":"Wind万得","summary":"香港万得通讯社综合报道，因成功大举押注特斯拉，方舟投资（ARK Investment）旗舰基金方舟创新ETF（ARKK）从2019年一只名不见经传的主动型基金一跃成为2020年风头最劲的基金，收获15","content":"<p>香港万得通讯社综合报道，因成功大举押注<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>，方舟投资（ARK Investment）旗舰基金方舟创新ETF（ARKK）从2019年一只名不见经传的主动型基金一跃成为2020年风头最劲的基金，收获153%回报率的傲人业绩，使其创始人凯瑟琳·伍德（Cathie Wood）声名鹊起。但今年以来，这只规模220亿美元的ETF表现欠佳，过去六周遭遇大幅回撤，年内迄今下跌近9%。 过去一年其投资组合发生了怎样的变化，对投资者来说又意味着什么？</p>\n<p><img src=\"https://static.tigerbbs.com/e8de7432c6039cc766566908d9becef3\" tg-width=\"840\" tg-height=\"470\"></p>\n<p>据Barron's，一年前，ARKK还是一只小盘股基金，如今，其所持股票的平均市值已稳固在中盘股水平，且51%的资产为大公司股票。截至2月底，ARKK所持股票的平均市值从去年3月的50亿美元上升至390亿美元。值得注意的是，即便近期股价有所回调，占ARKK持仓比重最高的特斯拉过去一年的回报率仍达500%。</p>\n<p>许多主动型基金会对可买入和继续持有的公司的规模加以限制。ARKK并无这类限制，持股公司的市值大到5940亿美元的特斯拉，小到10亿美元的生物医药公司Cerus（CERS.US）。ARK客户投资组合经理Ren Leggi说，他们关注的不是市值，而是创新的方向。</p>\n<p>这仅仅部分解释了ARKK倾向购买市值较大公司的股票。过去几个月，该基金还在出售市值较小公司的股票，其中许多来自生物技术领域，包括Organovo Holdings（ONVO.US）、Seres Therapeutics（MCRB.US）、Compugen（CGEN.US）和Editas Medicine（EDIT.US）。</p>\n<p>与此同时，ARKK还增持了大量大型互联网公司股票，例如<a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings（PYPL.US）、Shopify（SHOP.US）、<a href=\"https://laohu8.com/S/ZM\">Zoom</a>（ZM.US）；此外，还有<a href=\"https://laohu8.com/S/00700\">腾讯控股</a>（00700）、<a href=\"https://laohu8.com/S/BIDU\">百度</a>（BIDU.US）、冬海、任天堂（NTDOY.US）等非美国公司ADR。去年7月时，ARKK并未持有这些股票。</p>\n<p>最近的交易也改变了ARKK持股的行业构成。2020年3月，生物技术和诊断行业在该基金投资组合中所占比重最大，分别为22%和15%，而到今年2月底，二者占比已降至14%和8%。同时，互联网和软件公司股票占比则从去年3月的各6%升至15%和9%。去年10月还不在ARKK持仓名单之列的Shopify（SHOP.US）成为了该基金第八大持股，占比为3.1%。</p>\n<p>不过，晨星投资组合策略师Amy Arnott称，与其他中盘成长型基金相比，ARKK在医疗保健领域的仓位相对较重，科技领域的仓位相对较轻。</p>\n<p>一些人猜测，转投较大型公司是ARKK空前增长的结果。过去一年，该基金吸引了160亿美元新资产。若这些资金被用于投资较小型公司，可能会迅速让ARKK在这些公司的持股比例上升到危险水平。从这个角度来说，将这笔资金投入流动性更好的大盘股是更安全的选择。</p>\n<p>而ARK否认最近的交易决定与市值有关，表示这些举动是出于信念、估值和战术考虑。ARK的Leggi称，公司自去年以来也一直在为市场修正做准备，增持大盘股是为了提供下行保护和类似现金的储备，以便在市场低迷时期以低价买入高度看好的股票。</p>\n<p>分析指出，从小盘股基金到中盘股基金，从偏向医疗保健到青睐互联网，ARKK投资组合特征的变化意味着该基金未来的波动性可能会降低。许多生物技术公司在产品获批之前缺乏现金流或收入，而互联网公司通常会有一些产品或服务在售。</p>\n<p>这或许意味着ARK今年的业绩表现会更接近2019年（回报率36%），而不是2020年。晨星的Arnott表示：“它仍然是一只极具进取空间的成长型基金。但随着资产增加，基金维持业绩优势的难度可能加大。”</p>\n<p>ARK的Leggi则认为，大公司不一定意味着低增长，事实上，在某些行业中，入行较早、规模较大的颠覆者已经确立了自己的地位，小型对手很难与之竞争。</p>\n<p>Leggi表示，已有许多规模较小的电动汽车制造商通过特殊目的收购公司（SPAC）借壳上市。“我们不投资它们，是因为鉴于资本密集的程度，我们认为它们不具备成为新领导者的有利地位。特斯拉遥遥领先。我们的投资组合不太可能出现像几年前那样多的小盘股敞口。”ARK日前发布了特斯拉的最新目标价，预测2025年上看3000美元，较上周五收盘价618.71美元高出近4倍。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARK旗下明星基金产品面临洗牌转变</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARK旗下明星基金产品面临洗牌转变\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/99\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/c71e30d1317b4a5cb20a41998e10ac68);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Wind万得 </p>\n<p class=\"h-time\">2021-03-29 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>香港万得通讯社综合报道，因成功大举押注<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>，方舟投资（ARK Investment）旗舰基金方舟创新ETF（ARKK）从2019年一只名不见经传的主动型基金一跃成为2020年风头最劲的基金，收获153%回报率的傲人业绩，使其创始人凯瑟琳·伍德（Cathie Wood）声名鹊起。但今年以来，这只规模220亿美元的ETF表现欠佳，过去六周遭遇大幅回撤，年内迄今下跌近9%。 过去一年其投资组合发生了怎样的变化，对投资者来说又意味着什么？</p>\n<p><img src=\"https://static.tigerbbs.com/e8de7432c6039cc766566908d9becef3\" tg-width=\"840\" tg-height=\"470\"></p>\n<p>据Barron's，一年前，ARKK还是一只小盘股基金，如今，其所持股票的平均市值已稳固在中盘股水平，且51%的资产为大公司股票。截至2月底，ARKK所持股票的平均市值从去年3月的50亿美元上升至390亿美元。值得注意的是，即便近期股价有所回调，占ARKK持仓比重最高的特斯拉过去一年的回报率仍达500%。</p>\n<p>许多主动型基金会对可买入和继续持有的公司的规模加以限制。ARKK并无这类限制，持股公司的市值大到5940亿美元的特斯拉，小到10亿美元的生物医药公司Cerus（CERS.US）。ARK客户投资组合经理Ren Leggi说，他们关注的不是市值，而是创新的方向。</p>\n<p>这仅仅部分解释了ARKK倾向购买市值较大公司的股票。过去几个月，该基金还在出售市值较小公司的股票，其中许多来自生物技术领域，包括Organovo Holdings（ONVO.US）、Seres Therapeutics（MCRB.US）、Compugen（CGEN.US）和Editas Medicine（EDIT.US）。</p>\n<p>与此同时，ARKK还增持了大量大型互联网公司股票，例如<a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings（PYPL.US）、Shopify（SHOP.US）、<a href=\"https://laohu8.com/S/ZM\">Zoom</a>（ZM.US）；此外，还有<a href=\"https://laohu8.com/S/00700\">腾讯控股</a>（00700）、<a href=\"https://laohu8.com/S/BIDU\">百度</a>（BIDU.US）、冬海、任天堂（NTDOY.US）等非美国公司ADR。去年7月时，ARKK并未持有这些股票。</p>\n<p>最近的交易也改变了ARKK持股的行业构成。2020年3月，生物技术和诊断行业在该基金投资组合中所占比重最大，分别为22%和15%，而到今年2月底，二者占比已降至14%和8%。同时，互联网和软件公司股票占比则从去年3月的各6%升至15%和9%。去年10月还不在ARKK持仓名单之列的Shopify（SHOP.US）成为了该基金第八大持股，占比为3.1%。</p>\n<p>不过，晨星投资组合策略师Amy Arnott称，与其他中盘成长型基金相比，ARKK在医疗保健领域的仓位相对较重，科技领域的仓位相对较轻。</p>\n<p>一些人猜测，转投较大型公司是ARKK空前增长的结果。过去一年，该基金吸引了160亿美元新资产。若这些资金被用于投资较小型公司，可能会迅速让ARKK在这些公司的持股比例上升到危险水平。从这个角度来说，将这笔资金投入流动性更好的大盘股是更安全的选择。</p>\n<p>而ARK否认最近的交易决定与市值有关，表示这些举动是出于信念、估值和战术考虑。ARK的Leggi称，公司自去年以来也一直在为市场修正做准备，增持大盘股是为了提供下行保护和类似现金的储备，以便在市场低迷时期以低价买入高度看好的股票。</p>\n<p>分析指出，从小盘股基金到中盘股基金，从偏向医疗保健到青睐互联网，ARKK投资组合特征的变化意味着该基金未来的波动性可能会降低。许多生物技术公司在产品获批之前缺乏现金流或收入，而互联网公司通常会有一些产品或服务在售。</p>\n<p>这或许意味着ARK今年的业绩表现会更接近2019年（回报率36%），而不是2020年。晨星的Arnott表示：“它仍然是一只极具进取空间的成长型基金。但随着资产增加，基金维持业绩优势的难度可能加大。”</p>\n<p>ARK的Leggi则认为，大公司不一定意味着低增长，事实上，在某些行业中，入行较早、规模较大的颠覆者已经确立了自己的地位，小型对手很难与之竞争。</p>\n<p>Leggi表示，已有许多规模较小的电动汽车制造商通过特殊目的收购公司（SPAC）借壳上市。“我们不投资它们，是因为鉴于资本密集的程度，我们认为它们不具备成为新领导者的有利地位。特斯拉遥遥领先。我们的投资组合不太可能出现像几年前那样多的小盘股敞口。”ARK日前发布了特斯拉的最新目标价，预测2025年上看3000美元，较上周五收盘价618.71美元高出近4倍。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c9f9b11afe8174b685e500ffa9494567","relate_stocks":{"ARKK":"ARK Innovation ETF"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2123237957","content_text":"香港万得通讯社综合报道，因成功大举押注特斯拉，方舟投资（ARK Investment）旗舰基金方舟创新ETF（ARKK）从2019年一只名不见经传的主动型基金一跃成为2020年风头最劲的基金，收获153%回报率的傲人业绩，使其创始人凯瑟琳·伍德（Cathie Wood）声名鹊起。但今年以来，这只规模220亿美元的ETF表现欠佳，过去六周遭遇大幅回撤，年内迄今下跌近9%。 过去一年其投资组合发生了怎样的变化，对投资者来说又意味着什么？\n\n据Barron's，一年前，ARKK还是一只小盘股基金，如今，其所持股票的平均市值已稳固在中盘股水平，且51%的资产为大公司股票。截至2月底，ARKK所持股票的平均市值从去年3月的50亿美元上升至390亿美元。值得注意的是，即便近期股价有所回调，占ARKK持仓比重最高的特斯拉过去一年的回报率仍达500%。\n许多主动型基金会对可买入和继续持有的公司的规模加以限制。ARKK并无这类限制，持股公司的市值大到5940亿美元的特斯拉，小到10亿美元的生物医药公司Cerus（CERS.US）。ARK客户投资组合经理Ren Leggi说，他们关注的不是市值，而是创新的方向。\n这仅仅部分解释了ARKK倾向购买市值较大公司的股票。过去几个月，该基金还在出售市值较小公司的股票，其中许多来自生物技术领域，包括Organovo Holdings（ONVO.US）、Seres Therapeutics（MCRB.US）、Compugen（CGEN.US）和Editas Medicine（EDIT.US）。\n与此同时，ARKK还增持了大量大型互联网公司股票，例如PayPal Holdings（PYPL.US）、Shopify（SHOP.US）、Zoom（ZM.US）；此外，还有腾讯控股（00700）、百度（BIDU.US）、冬海、任天堂（NTDOY.US）等非美国公司ADR。去年7月时，ARKK并未持有这些股票。\n最近的交易也改变了ARKK持股的行业构成。2020年3月，生物技术和诊断行业在该基金投资组合中所占比重最大，分别为22%和15%，而到今年2月底，二者占比已降至14%和8%。同时，互联网和软件公司股票占比则从去年3月的各6%升至15%和9%。去年10月还不在ARKK持仓名单之列的Shopify（SHOP.US）成为了该基金第八大持股，占比为3.1%。\n不过，晨星投资组合策略师Amy Arnott称，与其他中盘成长型基金相比，ARKK在医疗保健领域的仓位相对较重，科技领域的仓位相对较轻。\n一些人猜测，转投较大型公司是ARKK空前增长的结果。过去一年，该基金吸引了160亿美元新资产。若这些资金被用于投资较小型公司，可能会迅速让ARKK在这些公司的持股比例上升到危险水平。从这个角度来说，将这笔资金投入流动性更好的大盘股是更安全的选择。\n而ARK否认最近的交易决定与市值有关，表示这些举动是出于信念、估值和战术考虑。ARK的Leggi称，公司自去年以来也一直在为市场修正做准备，增持大盘股是为了提供下行保护和类似现金的储备，以便在市场低迷时期以低价买入高度看好的股票。\n分析指出，从小盘股基金到中盘股基金，从偏向医疗保健到青睐互联网，ARKK投资组合特征的变化意味着该基金未来的波动性可能会降低。许多生物技术公司在产品获批之前缺乏现金流或收入，而互联网公司通常会有一些产品或服务在售。\n这或许意味着ARK今年的业绩表现会更接近2019年（回报率36%），而不是2020年。晨星的Arnott表示：“它仍然是一只极具进取空间的成长型基金。但随着资产增加，基金维持业绩优势的难度可能加大。”\nARK的Leggi则认为，大公司不一定意味着低增长，事实上，在某些行业中，入行较早、规模较大的颠覆者已经确立了自己的地位，小型对手很难与之竞争。\nLeggi表示，已有许多规模较小的电动汽车制造商通过特殊目的收购公司（SPAC）借壳上市。“我们不投资它们，是因为鉴于资本密集的程度，我们认为它们不具备成为新领导者的有利地位。特斯拉遥遥领先。我们的投资组合不太可能出现像几年前那样多的小盘股敞口。”ARK日前发布了特斯拉的最新目标价，预测2025年上看3000美元，较上周五收盘价618.71美元高出近4倍。","news_type":1},"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":328245287,"gmtCreate":1615535613449,"gmtModify":1703490567126,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"完蛋","listText":"完蛋","text":"完蛋","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/328245287","repostId":"1115768372","repostType":4,"repost":{"id":"1115768372","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1615535426,"share":"https://www.laohu8.com/m/news/1115768372?lang=&edition=full","pubTime":"2021-03-12 15:50","market":"hk","language":"zh","title":"恒生指数跌超2%，京东、腾讯大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1115768372","media":"老虎资讯综合","summary":"3月12日，十年期美债收益率突破1.6%，日内涨4.79%。受此影响，香港恒生指数跌幅扩大至2%，京东集团、华虹半导体跌超5%，美团、腾讯控股跌超4%。","content":"<p>3月12日，十年期美债收益率突破1.6%，日内涨4.79%。受此影响，香港恒生指数跌幅扩大至2%，京东集团、华虹半导体跌超5%，美团、腾讯控股跌超4%。</p><p><img src=\"https://static.tigerbbs.com/b9be3b102707d2cfebd3572207449fc3\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒生指数跌超2%，京东、腾讯大跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒生指数跌超2%，京东、腾讯大跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-03-12 15:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3月12日，十年期美债收益率突破1.6%，日内涨4.79%。受此影响，香港恒生指数跌幅扩大至2%，京东集团、华虹半导体跌超5%，美团、腾讯控股跌超4%。</p><p><img src=\"https://static.tigerbbs.com/b9be3b102707d2cfebd3572207449fc3\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","relate_stocks":{"HSI":"恒生指数"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115768372","content_text":"3月12日，十年期美债收益率突破1.6%，日内涨4.79%。受此影响，香港恒生指数跌幅扩大至2%，京东集团、华虹半导体跌超5%，美团、腾讯控股跌超4%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":406,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":328696901,"gmtCreate":1615517640303,"gmtModify":1703490317208,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"赞","listText":"赞","text":"赞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/328696901","repostId":"2118397489","repostType":4,"isVote":1,"tweetType":1,"viewCount":242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":316595363,"gmtCreate":1611936403752,"gmtModify":1703756788259,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"太棒了","listText":"太棒了","text":"太棒了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/316595363","repostId":"1111343117","repostType":4,"repost":{"id":"1111343117","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1611935882,"share":"https://www.laohu8.com/m/news/1111343117?lang=&edition=full","pubTime":"2021-01-29 23:58","market":"us","language":"zh","title":"今年以来游戏驿站看空者损失197.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111343117","media":"老虎资讯综合","summary":"金融数据公司S3 Partners数据显示，按市值计价，今年迄今为止游戏驿站看空者的损失为197.5亿美元，游戏驿站空头头寸规模112亿美元，仅次于特斯拉和苹果，位列第三。过去7天，游戏驿站空头头寸下","content":"<p>金融数据公司S3 Partners数据显示，按市值计价，今年迄今为止<a href=\"https://laohu8.com/S/GME\">游戏驿站</a>看空者的损失为197.5亿美元，游戏驿站空头头寸规模112亿美元，仅次于特斯拉和苹果，位列第三。过去7天，游戏驿站空头头寸下降了8%，至5783万股。</p><p><img src=\"https://static.tigerbbs.com/d2277924146bc8160bbe96674fdf1278\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>今年以来游戏驿站看空者损失197.5亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n今年以来游戏驿站看空者损失197.5亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-01-29 23:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>金融数据公司S3 Partners数据显示，按市值计价，今年迄今为止<a href=\"https://laohu8.com/S/GME\">游戏驿站</a>看空者的损失为197.5亿美元，游戏驿站空头头寸规模112亿美元，仅次于特斯拉和苹果，位列第三。过去7天，游戏驿站空头头寸下降了8%，至5783万股。</p><p><img src=\"https://static.tigerbbs.com/d2277924146bc8160bbe96674fdf1278\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/b1fdaab121d904fee30d8fe32e39819a","relate_stocks":{"GME":"游戏驿站"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111343117","content_text":"金融数据公司S3 Partners数据显示，按市值计价，今年迄今为止游戏驿站看空者的损失为197.5亿美元，游戏驿站空头头寸规模112亿美元，仅次于特斯拉和苹果，位列第三。过去7天，游戏驿站空头头寸下降了8%，至5783万股。","news_type":1},"isVote":1,"tweetType":1,"viewCount":507,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667803686145","idStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":153576645,"gmtCreate":1625039703287,"gmtModify":1633945558096,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"为什么辉瑞股票最近不能涨！","listText":"为什么辉瑞股票最近不能涨！","text":"为什么辉瑞股票最近不能涨！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153576645","repostId":"2147894605","repostType":2,"isVote":1,"tweetType":1,"viewCount":1840,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":167367006,"gmtCreate":1624248014505,"gmtModify":1634008915198,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/167367006","repostId":"2145704430","repostType":4,"repost":{"id":"2145704430","kind":"highlight","weMediaInfo":{"introduction":"致力于提供最及时的财经资讯，最专业的解读分析，覆盖宏观经济、金融机构、A股市场、上市公司、投资理财等财经领域。","home_visible":1,"media_name":"券商中国","id":"9","head_image":"https://static.tigerbbs.com/d482d56459984e8c86a6a137295b3c4f"},"pubTimestamp":1624204860,"share":"https://www.laohu8.com/m/news/2145704430?lang=&edition=full","pubTime":"2021-06-21 00:01","market":"hk","language":"zh","title":"格力超级员工持股计划来了！员工可五折\"买股票\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704430","media":"券商中国","summary":"此次员工持股计划涉及多达12000人，几乎涉及公司高管、中层干部以及关键岗位的员工，是格力史上最大规模的员工持股计划，并且按照此前筹划的员工持股3%的计划，接下来或还有第二期。值得注意的是，虽然员工可以5折认购格力电器股票，但此次员工持股计划也设置了的业绩考核期。两个月后，格力电器终于公布了第一期员工持股计划（草案）。多达12000人的员工持股计划，是格力史上最大规模的员工持股计划。","content":"<p>家电龙头<a href=\"https://laohu8.com/S/000651\">格力电器</a>筹划的员工持股计划终于出炉！</p>\n<p>6月20日晚间，格力电器公布第一期员工持股计划，拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，占公司总股本的1.8%，购买价格为27.68元/股，即所回购股份均价的50%。</p>\n<p><b>此次员工持股计划涉及多达12000人，几乎涉及公司高管、中层干部以及关键岗位的员工，是格力史上最大规模的员工持股计划，并且按照此前筹划的员工持股3%的计划，接下来或还有第二期。</b></p>\n<p>其中，格力电器董事长董明珠拟认购3000万股，拟出资8.3亿元；而11992名中层干部、核心员工将认购7468.58万股，即员工人均认购6227股，人均17万元。</p>\n<p>值得注意的是，虽然员工可以5折认购格力电器股票，但此次员工持股计划也设置了的业绩考核期。业绩考核为2021年净利润为2020的110%，2022年为2020年的120%，且每股分红不低于2元。即2年后若完成考核，员工人均将赚18万元（包括2年分红1.2万元），董明珠则将收获9.5亿元（包括分红）。</p>\n<p>由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振，业绩又不及老对手美的，市值落后达2000亿元，此前还被富时罗素剔除了指数，可谓压力不小。如今，重磅推出持股计划，不知格力能否再次辉煌。</p>\n<p>格力史上最大规模员工持股计划</p>\n<p>今年4月15日，格力发布公告称，拟推出员工持股计划，此次员工持股计划拟持有的股票总数累计不超过公司股本总额的3%，单个员工拟所获股份权益对应的股票总数累计不超过公司股本总额的1%。</p>\n<p>两个月后，格力电器终于公布了第一期员工持股计划（草案）。拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，员工持股计划的存续期为3年，锁定期12个月。</p>\n<p>员工持股计划股票来源为公司回购专用账户中已回购的股份，股票规模为不超过 10836.58万股，占公司当前总股本的 1.80%。员工的认购价格为27.68元/股，为所回购股份均价的50%，5折认购也是此前市场所预期标准。</p>\n<p>此次员工持股计划的对象，包括公司董事（不含独立董事）、监事、 高级管理人员，以及公司及控股子公司经董事会认定对公司整体业绩和中长期发展具有重要作用的中层干部和核心员工。</p>\n<p>多达12000人的员工持股计划，是格力史上最大规模的员工持股计划。</p>\n<p><b>其中，格力电器董事长董明珠拟认购3000万股，占持股计划的27.68%，拟出资8.3亿元，张伟、庄培等6位高管均认购60万股，职工监事王法雯认购8万股。</b></p>\n<p>而11992名中层干部、核心员工将认购7468.58万股，占比68.92%，拟出资20.67亿元，即普通员工人均认购6227股，人均17万元。</p>\n<p><img src=\"https://static.tigerbbs.com/7c2fbb8d1fa64b5ea5d9ef74ecca584a\" tg-width=\"1080\" tg-height=\"868\" referrerpolicy=\"no-referrer\"></p>\n<p>公开信息显示，格力电器上一次大规模的股权激励还是2009年，当时大股东格力集团划转了1604.25万股格力电器股份，对格力电器6名高管以及1053名格力电器中层干部、业务骨干及控股子公司高管人员进行股权激励。当时格力电器董事长朱江洪和总裁董明珠受激励股份均为226万股。</p>\n<p>格力电器表示，推出员工持股计划的目的是进一步完善公司治理结构，建立健全公司长期、有效的激励约束机制，完善劳动者与所有者的利益共享机制，提升公司管理团队的凝聚力和公司竞争力，吸引和保留优秀的人才，为公司的持续快速发展注入新的动力。</p>\n<p>设定2年业绩考核指标，每年现金分红超100亿</p>\n<p><b>值得注意的是，虽然员工可以5折认购格力电器股票，但此次格力电器的员工持股计划也设置了严格的业绩考核期。</b></p>\n<p>业绩考核将分两期，每期可归属的比例最高为50%，并设定公司层面和个人层面的业绩考核指标，达到业绩考核指标才能获得权益。</p>\n<p>其中，第一个归属期，业绩考核指标为2021年净利润较2020 年增长不低于10%，第二个归属期，2022年净利润较2020年增长不低20%，且当年每股现金分红不低于2元或现金分红总额不低于当年净利润的50%。</p>\n<p><img src=\"https://static.tigerbbs.com/da2fafbf12a54c7fa74b35f7f3dba46b\" tg-width=\"912\" tg-height=\"201\" referrerpolicy=\"no-referrer\"></p>\n<p>值得注意的是，按照2020年格力221.8亿元的净利润计算，2021年净利润应达到243.98亿元，2022年净利润则需要达到266.16亿元，将超越2018年实现的262亿元的历史纪录。值得注意的是，去年四季度格力净利润高达85亿元，是历史上单季度最高的利润，即格力并没有“隐藏”利润、降低持股计划完成的难度。</p>\n<p>同时，这个业绩考核基本也明确了接下来2年格力现金分红的力度，即不低于2元或50%，每年现金分红将超过100亿元，这对不少投资者而言，将是一个比较确定性的利好。</p>\n<p>格力电器表示，第一个考核归属期届满，若公司业绩考核指标不达标，则递延至第二个考核归属期合并考核。而个人绩效考核则要求公司业绩达标且个人绩效考核等级为C级及以上，才可获得相应权益归属。</p>\n<p><img src=\"https://static.tigerbbs.com/1c4a5a88e2b74b58bad0ea2654ea4096\" tg-width=\"884\" tg-height=\"186\" referrerpolicy=\"no-referrer\"></p>\n<p>若第二个考核归属期届满后，公司业绩考核不达标，将由管理委员会决策处置，包括注销或由择机出售股票等，将以处置所获金额为限，返还对应持有人缴纳的原始出资额，剩余收益（如有）返还公司。</p>\n<p>即公司业绩考核指标没有完成，则所有人无法享受权益；公司业绩考核指标达到，个人业绩考核不达标，则个人无法享受该权益。</p>\n<p>格力股价能否走出阴霾？</p>\n<p>由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振。</p>\n<p>今年以来，格力股价已经跌了13.34%，市值为3229亿元，表现远不及上证指数，沪指年内上涨超2%。另外一边，美的由于去年大涨，今年跌幅达23.79%，但市值仍然领先格力电器近2000亿元。</p>\n<p><b>从业绩来看，过去五年，2016-2020年，美的的营收分别为1598亿、2419亿元、2618亿元、2794亿元、2857亿元，营收保持良好的增长态势；而格力过去五年营收分别为，1101亿元、1500亿元、2000亿元、2005亿元、1704亿元，在营收上渐渐被美的拉开了差距。</b></p>\n<p>同时，格力空调在终端与美的溢价也逐渐缩小，即两者品牌力的差距在缩小；而在国际化上，格力则不及美的，2020年美的的国际销售1210亿元，占营收比超过42%；境外收入毛利率25.45%，格力的国际销售200亿元，占营收比例不足12%，毛利率为12.13%：在多元化上，格力也不及美的，美的的生活电器，洗衣机、冰箱、电饭煲等，在多个领域成为行业龙头。</p>\n<p><b>正是因为美的过去几年的快速成长和超越，使得不少投资者看好美的，而看空格力。</b></p>\n<p>不过，2020年，虽然遭遇疫情，格力优势的线下渠道重挫，但格力坚决的进行渠道改革发力线上，董明珠更是进行多场直播带货。去年四季度实现净利润85亿元，创下历史上单季度最高的利润。2021年一季度，公司实现营收同比增长60.30%，归母净利润同比增长120.98%。</p>\n<p>东莞证券在研报中指出，2021年一季度格力业绩虽然仍未恢复至2019年同期水平，但公司业绩已出现恢复性增长。根据产业在线，格力空调2021年Q1内销量同比增长69.4%，外销量同比增长6.4%，反映出公司渠道改革和管理优化取得阶段性进展。</p>\n<p>董明珠在最新的采访中表示，坚持<a href=\"https://laohu8.com/S/300959\">线上线下</a>的销售模式，绝对不能单一走线上，也不能单一走线下。</p>\n<p><a href=\"https://laohu8.com/S/002736\">国信证券</a>指出，格力三次大额回购彰显信心，看好公司长期发展价值。同时，5月空调内销排产增速领先，销售均价迎来持续上涨。随着员工持股计划落地在即，格力的治理结构改善可期。空调主业不断扩展应用领域，在冰洗等其他家电产品上快速开拓，在<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>装备、精密模具、新能源、半导体等新兴产业实现突破，未来有望持续为公司贡献增长动力。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>格力超级员工持股计划来了！员工可五折\"买股票\"</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n格力超级员工持股计划来了！员工可五折\"买股票\"\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/9\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d482d56459984e8c86a6a137295b3c4f);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">券商中国 </p>\n<p class=\"h-time\">2021-06-21 00:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>家电龙头<a href=\"https://laohu8.com/S/000651\">格力电器</a>筹划的员工持股计划终于出炉！</p>\n<p>6月20日晚间，格力电器公布第一期员工持股计划，拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，占公司总股本的1.8%，购买价格为27.68元/股，即所回购股份均价的50%。</p>\n<p><b>此次员工持股计划涉及多达12000人，几乎涉及公司高管、中层干部以及关键岗位的员工，是格力史上最大规模的员工持股计划，并且按照此前筹划的员工持股3%的计划，接下来或还有第二期。</b></p>\n<p>其中，格力电器董事长董明珠拟认购3000万股，拟出资8.3亿元；而11992名中层干部、核心员工将认购7468.58万股，即员工人均认购6227股，人均17万元。</p>\n<p>值得注意的是，虽然员工可以5折认购格力电器股票，但此次员工持股计划也设置了的业绩考核期。业绩考核为2021年净利润为2020的110%，2022年为2020年的120%，且每股分红不低于2元。即2年后若完成考核，员工人均将赚18万元（包括2年分红1.2万元），董明珠则将收获9.5亿元（包括分红）。</p>\n<p>由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振，业绩又不及老对手美的，市值落后达2000亿元，此前还被富时罗素剔除了指数，可谓压力不小。如今，重磅推出持股计划，不知格力能否再次辉煌。</p>\n<p>格力史上最大规模员工持股计划</p>\n<p>今年4月15日，格力发布公告称，拟推出员工持股计划，此次员工持股计划拟持有的股票总数累计不超过公司股本总额的3%，单个员工拟所获股份权益对应的股票总数累计不超过公司股本总额的1%。</p>\n<p>两个月后，格力电器终于公布了第一期员工持股计划（草案）。拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，员工持股计划的存续期为3年，锁定期12个月。</p>\n<p>员工持股计划股票来源为公司回购专用账户中已回购的股份，股票规模为不超过 10836.58万股，占公司当前总股本的 1.80%。员工的认购价格为27.68元/股，为所回购股份均价的50%，5折认购也是此前市场所预期标准。</p>\n<p>此次员工持股计划的对象，包括公司董事（不含独立董事）、监事、 高级管理人员，以及公司及控股子公司经董事会认定对公司整体业绩和中长期发展具有重要作用的中层干部和核心员工。</p>\n<p>多达12000人的员工持股计划，是格力史上最大规模的员工持股计划。</p>\n<p><b>其中，格力电器董事长董明珠拟认购3000万股，占持股计划的27.68%，拟出资8.3亿元，张伟、庄培等6位高管均认购60万股，职工监事王法雯认购8万股。</b></p>\n<p>而11992名中层干部、核心员工将认购7468.58万股，占比68.92%，拟出资20.67亿元，即普通员工人均认购6227股，人均17万元。</p>\n<p><img src=\"https://static.tigerbbs.com/7c2fbb8d1fa64b5ea5d9ef74ecca584a\" tg-width=\"1080\" tg-height=\"868\" referrerpolicy=\"no-referrer\"></p>\n<p>公开信息显示，格力电器上一次大规模的股权激励还是2009年，当时大股东格力集团划转了1604.25万股格力电器股份，对格力电器6名高管以及1053名格力电器中层干部、业务骨干及控股子公司高管人员进行股权激励。当时格力电器董事长朱江洪和总裁董明珠受激励股份均为226万股。</p>\n<p>格力电器表示，推出员工持股计划的目的是进一步完善公司治理结构，建立健全公司长期、有效的激励约束机制，完善劳动者与所有者的利益共享机制，提升公司管理团队的凝聚力和公司竞争力，吸引和保留优秀的人才，为公司的持续快速发展注入新的动力。</p>\n<p>设定2年业绩考核指标，每年现金分红超100亿</p>\n<p><b>值得注意的是，虽然员工可以5折认购格力电器股票，但此次格力电器的员工持股计划也设置了严格的业绩考核期。</b></p>\n<p>业绩考核将分两期，每期可归属的比例最高为50%，并设定公司层面和个人层面的业绩考核指标，达到业绩考核指标才能获得权益。</p>\n<p>其中，第一个归属期，业绩考核指标为2021年净利润较2020 年增长不低于10%，第二个归属期，2022年净利润较2020年增长不低20%，且当年每股现金分红不低于2元或现金分红总额不低于当年净利润的50%。</p>\n<p><img src=\"https://static.tigerbbs.com/da2fafbf12a54c7fa74b35f7f3dba46b\" tg-width=\"912\" tg-height=\"201\" referrerpolicy=\"no-referrer\"></p>\n<p>值得注意的是，按照2020年格力221.8亿元的净利润计算，2021年净利润应达到243.98亿元，2022年净利润则需要达到266.16亿元，将超越2018年实现的262亿元的历史纪录。值得注意的是，去年四季度格力净利润高达85亿元，是历史上单季度最高的利润，即格力并没有“隐藏”利润、降低持股计划完成的难度。</p>\n<p>同时，这个业绩考核基本也明确了接下来2年格力现金分红的力度，即不低于2元或50%，每年现金分红将超过100亿元，这对不少投资者而言，将是一个比较确定性的利好。</p>\n<p>格力电器表示，第一个考核归属期届满，若公司业绩考核指标不达标，则递延至第二个考核归属期合并考核。而个人绩效考核则要求公司业绩达标且个人绩效考核等级为C级及以上，才可获得相应权益归属。</p>\n<p><img src=\"https://static.tigerbbs.com/1c4a5a88e2b74b58bad0ea2654ea4096\" tg-width=\"884\" tg-height=\"186\" referrerpolicy=\"no-referrer\"></p>\n<p>若第二个考核归属期届满后，公司业绩考核不达标，将由管理委员会决策处置，包括注销或由择机出售股票等，将以处置所获金额为限，返还对应持有人缴纳的原始出资额，剩余收益（如有）返还公司。</p>\n<p>即公司业绩考核指标没有完成，则所有人无法享受权益；公司业绩考核指标达到，个人业绩考核不达标，则个人无法享受该权益。</p>\n<p>格力股价能否走出阴霾？</p>\n<p>由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振。</p>\n<p>今年以来，格力股价已经跌了13.34%，市值为3229亿元，表现远不及上证指数，沪指年内上涨超2%。另外一边，美的由于去年大涨，今年跌幅达23.79%，但市值仍然领先格力电器近2000亿元。</p>\n<p><b>从业绩来看，过去五年，2016-2020年，美的的营收分别为1598亿、2419亿元、2618亿元、2794亿元、2857亿元，营收保持良好的增长态势；而格力过去五年营收分别为，1101亿元、1500亿元、2000亿元、2005亿元、1704亿元，在营收上渐渐被美的拉开了差距。</b></p>\n<p>同时，格力空调在终端与美的溢价也逐渐缩小，即两者品牌力的差距在缩小；而在国际化上，格力则不及美的，2020年美的的国际销售1210亿元，占营收比超过42%；境外收入毛利率25.45%，格力的国际销售200亿元，占营收比例不足12%，毛利率为12.13%：在多元化上，格力也不及美的，美的的生活电器，洗衣机、冰箱、电饭煲等，在多个领域成为行业龙头。</p>\n<p><b>正是因为美的过去几年的快速成长和超越，使得不少投资者看好美的，而看空格力。</b></p>\n<p>不过，2020年，虽然遭遇疫情，格力优势的线下渠道重挫，但格力坚决的进行渠道改革发力线上，董明珠更是进行多场直播带货。去年四季度实现净利润85亿元，创下历史上单季度最高的利润。2021年一季度，公司实现营收同比增长60.30%，归母净利润同比增长120.98%。</p>\n<p>东莞证券在研报中指出，2021年一季度格力业绩虽然仍未恢复至2019年同期水平，但公司业绩已出现恢复性增长。根据产业在线，格力空调2021年Q1内销量同比增长69.4%，外销量同比增长6.4%，反映出公司渠道改革和管理优化取得阶段性进展。</p>\n<p>董明珠在最新的采访中表示，坚持<a href=\"https://laohu8.com/S/300959\">线上线下</a>的销售模式，绝对不能单一走线上，也不能单一走线下。</p>\n<p><a href=\"https://laohu8.com/S/002736\">国信证券</a>指出，格力三次大额回购彰显信心，看好公司长期发展价值。同时，5月空调内销排产增速领先，销售均价迎来持续上涨。随着员工持股计划落地在即，格力的治理结构改善可期。空调主业不断扩展应用领域，在冰洗等其他家电产品上快速开拓，在<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>装备、精密模具、新能源、半导体等新兴产业实现突破，未来有望持续为公司贡献增长动力。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/0dde210ffe3142859199a0f7aae41f0a","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704430","content_text":"家电龙头格力电器筹划的员工持股计划终于出炉！\n6月20日晚间，格力电器公布第一期员工持股计划，拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，占公司总股本的1.8%，购买价格为27.68元/股，即所回购股份均价的50%。\n此次员工持股计划涉及多达12000人，几乎涉及公司高管、中层干部以及关键岗位的员工，是格力史上最大规模的员工持股计划，并且按照此前筹划的员工持股3%的计划，接下来或还有第二期。\n其中，格力电器董事长董明珠拟认购3000万股，拟出资8.3亿元；而11992名中层干部、核心员工将认购7468.58万股，即员工人均认购6227股，人均17万元。\n值得注意的是，虽然员工可以5折认购格力电器股票，但此次员工持股计划也设置了的业绩考核期。业绩考核为2021年净利润为2020的110%，2022年为2020年的120%，且每股分红不低于2元。即2年后若完成考核，员工人均将赚18万元（包括2年分红1.2万元），董明珠则将收获9.5亿元（包括分红）。\n由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振，业绩又不及老对手美的，市值落后达2000亿元，此前还被富时罗素剔除了指数，可谓压力不小。如今，重磅推出持股计划，不知格力能否再次辉煌。\n格力史上最大规模员工持股计划\n今年4月15日，格力发布公告称，拟推出员工持股计划，此次员工持股计划拟持有的股票总数累计不超过公司股本总额的3%，单个员工拟所获股份权益对应的股票总数累计不超过公司股本总额的1%。\n两个月后，格力电器终于公布了第一期员工持股计划（草案）。拟参与员工持股计划的员工总人数不超过12000人，员工持股计划的资金规模不超过30亿元，员工持股计划的存续期为3年，锁定期12个月。\n员工持股计划股票来源为公司回购专用账户中已回购的股份，股票规模为不超过 10836.58万股，占公司当前总股本的 1.80%。员工的认购价格为27.68元/股，为所回购股份均价的50%，5折认购也是此前市场所预期标准。\n此次员工持股计划的对象，包括公司董事（不含独立董事）、监事、 高级管理人员，以及公司及控股子公司经董事会认定对公司整体业绩和中长期发展具有重要作用的中层干部和核心员工。\n多达12000人的员工持股计划，是格力史上最大规模的员工持股计划。\n其中，格力电器董事长董明珠拟认购3000万股，占持股计划的27.68%，拟出资8.3亿元，张伟、庄培等6位高管均认购60万股，职工监事王法雯认购8万股。\n而11992名中层干部、核心员工将认购7468.58万股，占比68.92%，拟出资20.67亿元，即普通员工人均认购6227股，人均17万元。\n\n公开信息显示，格力电器上一次大规模的股权激励还是2009年，当时大股东格力集团划转了1604.25万股格力电器股份，对格力电器6名高管以及1053名格力电器中层干部、业务骨干及控股子公司高管人员进行股权激励。当时格力电器董事长朱江洪和总裁董明珠受激励股份均为226万股。\n格力电器表示，推出员工持股计划的目的是进一步完善公司治理结构，建立健全公司长期、有效的激励约束机制，完善劳动者与所有者的利益共享机制，提升公司管理团队的凝聚力和公司竞争力，吸引和保留优秀的人才，为公司的持续快速发展注入新的动力。\n设定2年业绩考核指标，每年现金分红超100亿\n值得注意的是，虽然员工可以5折认购格力电器股票，但此次格力电器的员工持股计划也设置了严格的业绩考核期。\n业绩考核将分两期，每期可归属的比例最高为50%，并设定公司层面和个人层面的业绩考核指标，达到业绩考核指标才能获得权益。\n其中，第一个归属期，业绩考核指标为2021年净利润较2020 年增长不低于10%，第二个归属期，2022年净利润较2020年增长不低20%，且当年每股现金分红不低于2元或现金分红总额不低于当年净利润的50%。\n\n值得注意的是，按照2020年格力221.8亿元的净利润计算，2021年净利润应达到243.98亿元，2022年净利润则需要达到266.16亿元，将超越2018年实现的262亿元的历史纪录。值得注意的是，去年四季度格力净利润高达85亿元，是历史上单季度最高的利润，即格力并没有“隐藏”利润、降低持股计划完成的难度。\n同时，这个业绩考核基本也明确了接下来2年格力现金分红的力度，即不低于2元或50%，每年现金分红将超过100亿元，这对不少投资者而言，将是一个比较确定性的利好。\n格力电器表示，第一个考核归属期届满，若公司业绩考核指标不达标，则递延至第二个考核归属期合并考核。而个人绩效考核则要求公司业绩达标且个人绩效考核等级为C级及以上，才可获得相应权益归属。\n\n若第二个考核归属期届满后，公司业绩考核不达标，将由管理委员会决策处置，包括注销或由择机出售股票等，将以处置所获金额为限，返还对应持有人缴纳的原始出资额，剩余收益（如有）返还公司。\n即公司业绩考核指标没有完成，则所有人无法享受权益；公司业绩考核指标达到，个人业绩考核不达标，则个人无法享受该权益。\n格力股价能否走出阴霾？\n由于遭遇疫情和渠道改革的阵痛，格力电器的股价一直低迷不振。\n今年以来，格力股价已经跌了13.34%，市值为3229亿元，表现远不及上证指数，沪指年内上涨超2%。另外一边，美的由于去年大涨，今年跌幅达23.79%，但市值仍然领先格力电器近2000亿元。\n从业绩来看，过去五年，2016-2020年，美的的营收分别为1598亿、2419亿元、2618亿元、2794亿元、2857亿元，营收保持良好的增长态势；而格力过去五年营收分别为，1101亿元、1500亿元、2000亿元、2005亿元、1704亿元，在营收上渐渐被美的拉开了差距。\n同时，格力空调在终端与美的溢价也逐渐缩小，即两者品牌力的差距在缩小；而在国际化上，格力则不及美的，2020年美的的国际销售1210亿元，占营收比超过42%；境外收入毛利率25.45%，格力的国际销售200亿元，占营收比例不足12%，毛利率为12.13%：在多元化上，格力也不及美的，美的的生活电器，洗衣机、冰箱、电饭煲等，在多个领域成为行业龙头。\n正是因为美的过去几年的快速成长和超越，使得不少投资者看好美的，而看空格力。\n不过，2020年，虽然遭遇疫情，格力优势的线下渠道重挫，但格力坚决的进行渠道改革发力线上，董明珠更是进行多场直播带货。去年四季度实现净利润85亿元，创下历史上单季度最高的利润。2021年一季度，公司实现营收同比增长60.30%，归母净利润同比增长120.98%。\n东莞证券在研报中指出，2021年一季度格力业绩虽然仍未恢复至2019年同期水平，但公司业绩已出现恢复性增长。根据产业在线，格力空调2021年Q1内销量同比增长69.4%，外销量同比增长6.4%，反映出公司渠道改革和管理优化取得阶段性进展。\n董明珠在最新的采访中表示，坚持线上线下的销售模式，绝对不能单一走线上，也不能单一走线下。\n国信证券指出，格力三次大额回购彰显信心，看好公司长期发展价值。同时，5月空调内销排产增速领先，销售均价迎来持续上涨。随着员工持股计划落地在即，格力的治理结构改善可期。空调主业不断扩展应用领域，在冰洗等其他家电产品上快速开拓，在智能装备、精密模具、新能源、半导体等新兴产业实现突破，未来有望持续为公司贡献增长动力。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":107316915,"gmtCreate":1620444292737,"gmtModify":1634198710271,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"完了完了","listText":"完了完了","text":"完了完了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/107316915","repostId":"1122718490","repostType":4,"isVote":1,"tweetType":1,"viewCount":395,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":106446393,"gmtCreate":1620141696012,"gmtModify":1634207490596,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"完了完了","listText":"完了完了","text":"完了完了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/106446393","repostId":"1108282071","repostType":4,"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":377003718,"gmtCreate":1619483076934,"gmtModify":1634212448049,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/377003718","repostId":"2130825346","repostType":4,"isVote":1,"tweetType":1,"viewCount":171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":378692735,"gmtCreate":1619020357927,"gmtModify":1634289148559,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"加仓","listText":"加仓","text":"加仓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/378692735","repostId":"1184581987","repostType":2,"repost":{"id":"1184581987","kind":"news","pubTimestamp":1618988658,"share":"https://www.laohu8.com/m/news/1184581987?lang=&edition=full","pubTime":"2021-04-21 15:04","market":"us","language":"en","title":"House Passes a Cannabis Banking Bill. Will the Senate Follow Suit?","url":"https://stock-news.laohu8.com/highlight/detail?id=1184581987","media":"Barrons","summary":"A bill to allow interstate banks to serve state-licensed cannabis operators was passed by a wide mar","content":"<p>A bill to allow interstate banks to serve state-licensed cannabis operators was passed by a wide margin Monday by the U.S. House of Representatives.The SAFE Banking Actrepresents the first move by a Democratic-controlled Congress to ease up on a fast-growing industry whose product is still illegal under federal law. Similar bills have passed the House before, but approval by the Senate and the White House look more likely this year.</p>\n<p>The bill passed in a strongly bipartisan vote of 321-101, and was timed for the day ahead of April 20,the annual 4/20 celebrationof cannabis reform. Against a 0.7% dip in Tuesday’s stock market, shares of U.S. cannabis operators fell in over-the-counter trading and on the Canadian Securities Exchange, where they have gone to list while waiting for big exchanges to accept them. The just-passed SAFE Actwon’t open capital marketsto the industry.</p>\n<p>The stock of the largest U.S. chain, Curaleaf Holdings (ticker: CURLF), fell 2.8%, at $12.72. Green Thumb Industries (GITBF) hovered around $27, down 1.4%.Trulieve Cannabis(TCNNF) slipped 2.1%, at $36.72, while Cresco Labs (CRLBF) traded for $11.82, slipping 1.3%. Pot producers that confine their sales to Canada, such asCanopy Growth(CGC),Tilray(TLRY), and&nbsp;Aphria(APHA), all sold off by 5% or more, as the penalty box door loosened for their U.S. rivals.</p>\n<p>To emerge from banking’s sin bin, the U.S. operators need the Senate’s approval.Cannabis banking bills&nbsp;passed the House in three previous legislative cycles, only to stall in the Republican-controlled Senate. Now the Senate is run by Democrats like Chuck Schumer, who favors even&nbsp;more comprehensive marijuana reform, so the modest banking measure may make it to President Joe Biden’s desk.</p>\n<p>The president has more urgent priorities than weed legalization, but the SAFE Act is seen as a public safety measure that will free cannabis businesses from handling dangerous stacks of cash. It’s hard to argue against that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>House Passes a Cannabis Banking Bill. Will the Senate Follow Suit?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHouse Passes a Cannabis Banking Bill. Will the Senate Follow Suit?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 15:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/house-passes-a-cannabis-banking-bill-will-the-senate-follow-suit-51618936166?mod=hp_LEAD_4><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A bill to allow interstate banks to serve state-licensed cannabis operators was passed by a wide margin Monday by the U.S. House of Representatives.The SAFE Banking Actrepresents the first move by a ...</p>\n\n<a href=\"https://www.barrons.com/articles/house-passes-a-cannabis-banking-bill-will-the-senate-follow-suit-51618936166?mod=hp_LEAD_4\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MJ":"Amplify Alternative Harvest ETF","ACB":"奥罗拉大麻公司","APHA":"Aphria Inc.","CRON":"Cronos Group Inc.","TLRY":"Tilray Inc.","CGC":"Canopy Growth Corporation","SNDL":"SNDL Inc."},"source_url":"https://www.barrons.com/articles/house-passes-a-cannabis-banking-bill-will-the-senate-follow-suit-51618936166?mod=hp_LEAD_4","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184581987","content_text":"A bill to allow interstate banks to serve state-licensed cannabis operators was passed by a wide margin Monday by the U.S. House of Representatives.The SAFE Banking Actrepresents the first move by a Democratic-controlled Congress to ease up on a fast-growing industry whose product is still illegal under federal law. Similar bills have passed the House before, but approval by the Senate and the White House look more likely this year.\nThe bill passed in a strongly bipartisan vote of 321-101, and was timed for the day ahead of April 20,the annual 4/20 celebrationof cannabis reform. Against a 0.7% dip in Tuesday’s stock market, shares of U.S. cannabis operators fell in over-the-counter trading and on the Canadian Securities Exchange, where they have gone to list while waiting for big exchanges to accept them. The just-passed SAFE Actwon’t open capital marketsto the industry.\nThe stock of the largest U.S. chain, Curaleaf Holdings (ticker: CURLF), fell 2.8%, at $12.72. Green Thumb Industries (GITBF) hovered around $27, down 1.4%.Trulieve Cannabis(TCNNF) slipped 2.1%, at $36.72, while Cresco Labs (CRLBF) traded for $11.82, slipping 1.3%. Pot producers that confine their sales to Canada, such asCanopy Growth(CGC),Tilray(TLRY), and Aphria(APHA), all sold off by 5% or more, as the penalty box door loosened for their U.S. rivals.\nTo emerge from banking’s sin bin, the U.S. operators need the Senate’s approval.Cannabis banking bills passed the House in three previous legislative cycles, only to stall in the Republican-controlled Senate. Now the Senate is run by Democrats like Chuck Schumer, who favors even more comprehensive marijuana reform, so the modest banking measure may make it to President Joe Biden’s desk.\nThe president has more urgent priorities than weed legalization, but the SAFE Act is seen as a public safety measure that will free cannabis businesses from handling dangerous stacks of cash. It’s hard to argue against that.","news_type":1},"isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":360630503,"gmtCreate":1613898667302,"gmtModify":1634551911861,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"赞","listText":"赞","text":"赞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/360630503","repostId":"1129445314","repostType":4,"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":384645729,"gmtCreate":1613651761961,"gmtModify":1634552788149,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"加码。老虎证券，我的最爱。","listText":"加码。老虎证券，我的最爱。","text":"加码。老虎证券，我的最爱。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/384645729","repostId":"2112834866","repostType":2,"isVote":1,"tweetType":1,"viewCount":204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":381677534,"gmtCreate":1612966759828,"gmtModify":1703767597206,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"恭喜发财","listText":"恭喜发财","text":"恭喜发财","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/381677534","repostId":"1126709563","repostType":4,"isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":162233342,"gmtCreate":1624064111486,"gmtModify":1634023390630,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567856328974744","idStr":"3567856328974744"},"themes":[],"htmlText":"完了完了","listText":"完了完了","text":"完了完了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/162233342","repostId":"1145549454","repostType":4,"isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}